<link rel="stylesheet" href="https://bootswatch.com/4/flatly/bootstrap.min.css"><link rel="stylesheet" href="style.css"><script src="https://ajax.googleapis.com/ajax/libs/jquery/3.5.1/jquery.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.16.0/umd/popper.min.js"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.5.2/js/bootstrap.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1">
<div class="header"><div class="top_text"><p id="home">01/31/23</p><p class="summary"><strong> <em>Summary: New data in 3 studies; Expedited timeline in 11 studies; 14 new studies; 2 new IND acceptances; 1 new approval.</em> </strong></p></div><div id="images" class="logos"><img src="data:image/png;base64,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" alt="Lexidyne Logo" width="150" class="lex"><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><p class="logos">           </p><img src="data:image/png;base64,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" alt="Janssen Logo" width="150" class="jj"> </div></div><h1>Clinical Trials Weekly Digest</h1><br>

<h4><a href="#clinical">Clinical Results Press Releases</a></h4>
<h4><a href="#new_lc">Lung Cancer</a></h4>
<h4><a href="#new_it">Intratumoral</a></h4>
<h4><a href="#new_ct">Cytotoxic</a></h4>
<h4><a href="#new_ia">Immune Activation</a></h4>
<h4><a href="#approvals">Drug Approvals / Applications</a></h4>

<form action="https://getform.io/f/387eb37d-4992-430e-99b3-0bd1f47d1fb2"method="POST" id="interest_form" enctype="multipart/form-data" name="interest_form"><div class="form-group"><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ###### CLINICAL RESULTS ####### -->
<!-- ############################### -->
<!-- ############################### -->

<h2 id="clinical">Clinical Results Press Releases</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>C4 Therapeutics</td>
    <td>C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946 an Orally Bioavailable BiDAC Degrader in BRAF V600 Mutant Solid Tumors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05668585" target="_blank">NCT05668585</a></td><td><select class="form-select" id="select_form_1" name="NCT05668585"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Aptose</td>
    <td>Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03850574" target="_blank">NCT03850574</a></td><td><select class="form-select" id="select_form_2" name="NCT03850574"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Marengo Therapeutics</td>
    <td>Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR V Directed Antibody-Fusion Molecule STAR0602 in Cancer Patients Refractory to Anti-PD1 Therapy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05592626" target="_blank">START-001 (NCT05592626)</a></td><td><select class="form-select" id="select_form_3" name="NCT05592626"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Bristol Myers Squibb</td>
    <td>Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03331198" target="_blank">TRANSCEND CLL 004 (NCT03331198)</a></td><td><select class="form-select" id="select_form_4" name="NCT03331198"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Enlivex</td>
    <td>Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05581719" target="_blank">NCT05581719</a></td><td><select class="form-select" id="select_form_5" name="NCT05581719"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Mersana Therapeutics</td>
    <td>Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05514717" target="_blank">NCT05514717</a></td><td><select class="form-select" id="select_form_6" name="NCT05514717"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Allogene Therapeutics</td>
    <td>Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04093596" target="_blank">UNIVERSAL (NCT04093596)</a></td><td><select class="form-select" id="select_form_7" name="NCT04093596"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>AmMax Bio</td>
    <td>AmMax Bio Announces First Patients Dosed in Phase 2b Study of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05349643" target="_blank">NCT05349643</a></td><td><select class="form-select" id="select_form_8" name="NCT05349643"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Daiichi Sankyo</td>
    <td>TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05555732" target="_blank">TROPION-Lung07 (NCT05555732)</a></td><td><select class="form-select" id="select_form_9" name="NCT05555732"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Legend Biotech</td>
    <td>Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI (ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04181827" target="_blank">CARTITUDE-4 (NCT04181827)</a></td><td><select class="form-select" id="select_form_10" name="NCT04181827"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo1" class="accordion-toggle">    <td>Oncotelic</td>
    <td>Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/" target="_blank"></a></td><td><select class="form-select" id="select_form_11" name=""><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>

<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW LC ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_lc">New Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Advanced solid malignancies</td>
    <td>23andMe Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_1">Study Arms</button></td>
    <td>23ME-00610</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05199272" target="_blank">NCT05199272</a></td><td><select class="form-select" id="select_form_12" name="NCT05199272"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Clear Cell Renal Cell Carcinoma Metastatic; TNBC - Triple-Negative Breast Cancer; Head and Neck Cancer; Non-small-cell Lung Carcinoma; Mesothelioma Malignant</td>
    <td>Mabpro a.s.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_2">Study Arms</button></td>
    <td>CA9hu-1</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05698238" target="_blank">NCT05698238</a></td><td><select class="form-select" id="select_form_13" name="NCT05698238"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Extensive Stage Small Cell Lung Cancer (ES-SCLC)</td>
    <td>Genprex Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_3">Study Arms</button></td>
    <td><p>quaratusugene ozeplasmid; atezolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_502">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05703971" target="_blank">NCT05703971</a></td><td><select class="form-select" id="select_form_14" name="NCT05703971"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Solid Tumors</td>
    <td>DEKA Biosciences</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_4">Study Arms</button></td>
    <td>DK210 (EGFR); Radiation therapy; Immune checkpoint blockers; Chemotherapy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05704985" target="_blank">NCT05704985</a></td><td><select class="form-select" id="select_form_15" name="NCT05704985"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Locally advanced and metastatic non small cell lung cancer</td>
    <td>Kartos Therapeutics Inc.</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_5">Study Arms</button></td>
    <td><p>Navtemadlin; Navtemadlin Placebo; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_504">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05705466" target="_blank">NCT05705466</a></td><td><select class="form-select" id="select_form_16" name="NCT05705466"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Nonsmall Cell Lung Cancer Stage III; Unresectable Non-Small Cell Lung Carcinoma</td>
    <td>Wake Forest University Health Sciences</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_6">Study Arms</button></td>
    <td><p>Durvalumab; the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30); COPD Assessment Test (CAT); Modified Medical Research Council (mMRC) dyspnea scale</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_505">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05696782" target="_blank">NCT05696782</a></td><td><select class="form-select" id="select_form_17" name="NCT05696782"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>T790M mutation-positive NSCLC</td>
    <td>Samsung Medical Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_7">Study Arms</button></td>
    <td>Lazertinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05701384" target="_blank">NCT05701384</a></td><td><select class="form-select" id="select_form_18" name="NCT05701384"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Advanced renal cell carcinoma mesothelioma or osteosarcoma</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_8">Study Arms</button></td>
    <td><p>CAR.70/IL15-transduced CB-derived NK cells; Fludarabine phosphate; Cyclophosphamide</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_507">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05703854" target="_blank">NCT05703854</a></td><td><select class="form-select" id="select_form_19" name="NCT05703854"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>ES SCLC</td>
    <td>Fondazione IRCCS Istituto Nazionale dei Tumori Milano</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_9">Study Arms</button></td>
    <td><p>Cyclic 5-day calorie restriction; Atezolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_508">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05703997" target="_blank">NCT05703997</a></td><td><select class="form-select" id="select_form_20" name="NCT05703997"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>EGFR- or LKB1/STK11-mutant NSCLC</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_10">Study Arms</button></td>
    <td><p>Cemiplimab; Kevzara (Sarilumab)</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_509">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05704634" target="_blank">NCT05704634</a></td><td><select class="form-select" id="select_form_21" name="NCT05704634"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo2" class="accordion-toggle">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_1" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients will receive escalating doses of 23ME-00610|Patients will receive the recommended dose(s) of 23ME-00610</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: 23ME-00610</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part A: Incidence and severity of dose-limiting toxicities (DLTs)|Part B adolescents: Incidence and severity of dose-limiting toxicities (DLTs)|Part A: Incidence and severity of adverse events (AEs)|Part B adolescents: Incidence and severity of adverse events (AEs)|Part A: Incidence and severity of serious adverse events (SAEs)|Part B adolescents: Incidence and severity of serious adverse events (SAEs)|Part A: Incidence of withdrawals due to AEs|Part B adolescents: Incidence of withdrawals due to AEs|Part B: Objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR based on investigator assessment against RECIST 1.1 criteria</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From baseline until disease progression (up to 5 years); Up to 90 days post treatment; 21 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_2" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: CA9hu-1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of adverse events to CA9hi-1 and grading their severity according to the National Cancer Institute's Common Terminology Criteria for adverse Events (NCI CTCAE) Version 4.02.|Number of patients reaching the dose levels of 750 mg of CA9hu-1 without any dose limiting toxicities.|Number of patients reaching pharmacologically active dose measurement of CA9hu-1|Maximum tolerated dose of CA91hu-1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The objective is to determine a dose at which no more than one patient out of up to six patients at the same dose level experience a highly probable or probable CA9hu-1 related dose limiting toxicity.; The primary objective of this outcome is to establish the safety and toxicity profile of hu-CA91.; The objective of this outcome is to perform a dose escalation of of CA9hu-1 to levels of 750mg without any dose limiting toxicities.; The objective of this outcome is to determine number of patients in whom the pharmacologically active dose of CA9hu-1 wil be reached by measurement of plasma concentrations of the CA9hu-1. In order to reach the proposed pharmacologically active dose the plasma levels of 200 +/- 100 nM are necessary.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>4 weeks; 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_3" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Up to 2 sequential dose selection cohorts will be treated with quaratusugene ozeplasmid (intravenous (IV) administration once every 21 days) plus atezolizumab (1200 mg IV administration once every 21 days) until disease progression or unacceptable toxicity.||Quaratusugene ozeplasmid doses will be evaluated (0.09 [starting dose] and 0.12 mg/kg) until the RP2D is identified.|Patients will be treated with the RP2D of quaratusugene ozeplasmid (IV administration once every 21 days) plus atezolizumab (1200 mg IV administration once every 21 days) until disease progression or unacceptable toxicity</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: atezolizumab; Biological: quaratusugene ozeplasmid</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) - Phase 1|Progression-Free Survival Rate (PFSR) - Phase 2</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The MTD and/or RP2D of the combination of quaratusugene ozeplasmid and atezolizumab.; Note: if a MTD is not determined the RP2D will be selected based on all available data (safety PK PD and preliminary efficacy).; PFSR at 18 weeks according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>18-weeks from Day 1 of maintenance therapy; First 21-days at each dose level</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_4" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>DK210 (EGFR) will be administered as monotherapy three times per week via subcutaneous (SC) administration. Dose will be escalated from 0.025 mg/kg to 0.3 mg/kg or until unacceptable toxicity disease progression or withdrawal of consent. An expansion cohort at the optimal dose will be enrolled in parallel with the combination arms.|In patients with good tolerance of first line systemic therapy DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with second-line intravenous (IV) chemotherapy until unacceptable toxicity disease progression or withdrawal of consent|In patients with need of palliative radiation DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with short course radiation therapy (10 fractions or less) until unacceptable toxicity disease progression or withdrawal of consent|In patients with good tolerance of first line immunotherapy DK210 (EGFR) will be administered three times per week via subcutaneous (SC) administration in combination with intravenous (IV) immune checkpoint blockers until unacceptable toxicity disease progression or withdrawal of consent</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Chemotherapy; Biological: DK210 (EGFR); Biological: Immune checkpoint blockers; Radiation: Radiation therapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of Adverse Events (AEs) with DK210 (EGFR)|Identify recommended dose of DK210 (EGFR)|Incidence of Adverse Events (AE) of DK210 (EGFR) in combination with radiation chemotherapy or checkpoint blockers in Parts B C D</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Based on toxicities observed</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Minimum of 90 days from initiation of experimental therapy; Initiation of therapy up to day 90</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_5" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Placebo Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Navtemadlin will be administered orally once daily (QD) on days 1-7 in a 21-day cycle.||Pembrolizumab will be administered intravenously on Day 1 of a 21-day cycle.|Navtemadlin placebo will be administered orally once daily (QD) on days 1-7 in a 21-day cycle.||Pembrolizumab will be administered intravenously on Day 1 of a 21-day cycle.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pembrolizumab; Drug: Navtemadlin; Drug: Navtemadlin Placebo</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Phase 1b- To determine the recommended Phase 2 dose (RP2D)|Phase 2- To assess the treatment effect of navtemadlin plus pembrolizumab treatment on PFS compared with the treatment effect of navtemadlin placebo plus pembrolizumab treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS is defined as the time from randomization date to disease progression (assessed by the Independent Review Committee [IRC] per RECIST v1.1) or death whichever occurs first; The Safety Review Committee will determine the RP2D based on safety data of the combination of navtemadlin and pembrolizumab.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>64 Months; 21 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_6" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Standard of care test and procedures for cancer treatments along with Durvalumab treatment at physician's discretion</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Diagnostic Test: Modified Medical Research Council (mMRC) dyspnea scale; Other: the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30); Diagnostic Test: COPD Assessment Test (CAT); Drug: Durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Participants to Achieve Fidelity to Early Treatment with Durvalumab - Early Initiation (1-14 days)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Fidelity is defined as a dichotomous composite indicator (yes/no) that describes whether the patient received very early (1-7 days) initiation of Durvalumab as per protocol with all four of the following criteria having been met: (i) CT chest obtained after the last day of radiation therapy and before the first infusion of Durvalumab (ii) first infusion within 14 days of completing radiation therapy (iii) second and third doses received within 63 days of the first dose and (iv) all infusions at least 28 days apart.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>48 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_7" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Lazertinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>The dose reduction or treatment discontinuation rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Dose who received dosage below 160mg or discontinued due to the adverse event</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Total 24 months of study period</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_8" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will be assigned to a dose level of NK cells. A computer will decide by chance which of the dose level you will receive and this will not be based on the doctor's or patient's decision. Up to 5 dose levels of NK cells will be tested. Each new patient will receive a different dose. If any dose shows to be not tolerable this dose and the higher doses will not be given anymore.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Fludarabine phosphate; Drug: Cyclophosphamide; Drug: CAR.70/IL15-transduced CB-derived NK cells</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of Adverse Events Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>through study completion; an average of 1 year.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_9" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The experimental maintenance treatment will consist of:||triweekly cycles of 5-day calorie restriction (on days -2 through 2 of each cycle) in combination with|atezolizumab (at a dose of 1200 mg administered intravenously on day 0 of each cycle)||The experimental maintenance treatment will be administered until the occurrence of unacceptable toxic effects disease progression consent withdrawal or patient death.||Patients interrupting cyclic calorie restriction for any reason other than disease progression may continue the maintenance treatment with atezolizumab alone if clinically indicated.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Dietary Supplement: Cyclic 5-day calorie restriction; Drug: Atezolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>PFS rate at 6 months</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The percentage of patients not experiencing disease progression or death from any cause after 6 months from experimental maintenance treatment initiation</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6 months from experimental maintenance treatment initiation</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_10" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Each cohort is planned for 30 Participants with a total of 60 Participants. Participants who are treated in Run-In safety cohort can also be evaluated for efficacy in the molecularly define cohort A or B.|Each cohort is planned for 30 Participants with a total of 60 Participants. Participants who are treated in Run-In safety cohort can also be evaluated for efficacy in the molecularly define cohort A or B.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Kevzara (Sarilumab); Drug: Cemiplimab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of Adverse Events Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>through study completion; an average of 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## EXISTING LC ########## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_lc">Existing Trials - Lung Cancer</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 304 days; Enrollment decreased by: 88; Trial terminated; Primary Completion Date moved earlier by 479 days</strong></td>
    <td>Advanced non-small cell lung cancer</td>
    <td>Criterium Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_11">Study Arms</button></td>
    <td><p>brigatinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_510">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02706626" target="_blank">NCT02706626</a></td><td><select class="form-select" id="select_form_22" name="NCT02706626"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 671 days; Enrollment decreased by: 115; Trial terminated; Primary Completion Date moved earlier by 305 days</strong></td>
    <td>Advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations</td>
    <td>Worldwide Innovative Networking Association</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_12">Study Arms</button></td>
    <td><p>Avelumab; Axitinib; Palbociclib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_510">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03386929" target="_blank">NCT03386929</a></td><td><select class="form-select" id="select_form_23" name="NCT03386929"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Primary Completion Date moved earlier by 131 days</strong></td>
    <td>Metastatic Non-small Cell Lung Cancer; Metastatic Triple-negative Breast Cancer</td>
    <td>The Methodist Hospital Research Institute</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_13">Study Arms</button></td>
    <td><p>ADV/HSV-tk; Valacyclovir; SBRT; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_510">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03004183" target="_blank">NCT03004183</a></td><td><select class="form-select" id="select_form_24" name="NCT03004183"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Start Date moved earlier by 352 days</strong></td>
    <td>KRAS mutated unresectable locally advanced or metastatic NSCLC PDAC and CRC</td>
    <td>Biomea Fusion Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_14">Study Arms</button></td>
    <td>BMF-219</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05631574" target="_blank">NCT05631574</a></td><td><select class="form-select" id="select_form_25" name="NCT05631574"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 5329 days; Trial completed; Primary Completion Date pushed later by 138 days</strong></td>
    <td>Sdvanced solid tumors</td>
    <td>Fate Therapeutics</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_15">Study Arms</button></td>
    <td><p>FT516; Avelumab; Cyclophosphamide; Fludarabine; IL-2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_511">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04551885" target="_blank">NCT04551885</a></td><td><select class="form-select" id="select_form_26" name="NCT04551885"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 344 days; Trial completed</strong></td>
    <td>Malignant Mesothelioma (MPM)</td>
    <td>Memorial Sloan Kettering Cancer Center</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_16">Study Arms</button></td>
    <td><p>Avelumab; Stereotactic Body Radiation Therapy</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_511">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03399552" target="_blank">NCT03399552</a></td><td><select class="form-select" id="select_form_27" name="NCT03399552"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 107 days; Trial completed</strong></td>
    <td>Nonsquamous NSCLC patients that have untreated asymptomatic BM</td>
    <td>Spanish Lung Cancer Group</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_17">Study Arms</button></td>
    <td><p>Atezolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_511">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03526900" target="_blank">NCT03526900</a></td><td><select class="form-select" id="select_form_28" name="NCT03526900"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date moved earlier by 96 days; Trial completed</strong></td>
    <td>Stage IV Lung Adenocarcinoma</td>
    <td>Memorial Sloan Kettering Cancer Center</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_18">Study Arms</button></td>
    <td><p>Certolizumab; cisplatin; pemetrexed</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_511">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02120807" target="_blank">NCT02120807</a></td><td><select class="form-select" id="select_form_29" name="NCT02120807"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Non-small Cell Lung Cancer; Primary Neoplasm</td>
    <td>St. Joseph's Healthcare Hamilton</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_19">Study Arms</button></td>
    <td>Synapse 3D Lung Modelling; IC-Green (ICG)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03953144" target="_blank">NCT03953144</a></td><td><select class="form-select" id="select_form_30" name="NCT03953144"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Solid Tumors</td>
    <td>AbbVie</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_20">Study Arms</button></td>
    <td><p>ABBV-927; ABBV-368; ABBV-181; Carboplatin; Nab-paclitaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_512">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03893955" target="_blank">NCT03893955</a></td><td><select class="form-select" id="select_form_31" name="NCT03893955"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Changed status from recruiting to active</strong></td>
    <td>Relapsed or refractory advanced solid tumors</td>
    <td>Theratechnologies</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_21">Study Arms</button></td>
    <td>TH1902</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04706962" target="_blank">NCT04706962</a></td><td><select class="form-select" id="select_form_32" name="NCT04706962"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Trial completed</strong></td>
    <td>Advanced Solid Tumors</td>
    <td>Fate Therapeutics</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_22">Study Arms</button></td>
    <td><p>FT500; Nivolumab; Pembrolizumab; Atezolizumab; Cyclophosphamide; Fludarabine; IL-2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_513">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03841110" target="_blank">NCT03841110</a></td><td><select class="form-select" id="select_form_33" name="NCT03841110"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment decreased by: 122; Changed status from recruiting to active</strong></td>
    <td>Cutaneous Melanoma; Pleural Mesothelioma; HER2 Negative Breast Neoplasms; Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Ductal Adenocarcinoma</td>
    <td>Seagen Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_23">Study Arms</button></td>
    <td>SGN-CD228A</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04042480" target="_blank">NCT04042480</a></td><td><select class="form-select" id="select_form_34" name="NCT04042480"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Lung Cancer</td>
    <td>Jonsson Comprehensive Cancer Center</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_24">Study Arms</button></td>
    <td>Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside; Computed Tomography; Laboratory Biomarker Analysis; Positron Emission Tomography</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05558904" target="_blank">NCT05558904</a></td><td><select class="form-select" id="select_form_35" name="NCT05558904"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Start Date moved earlier by 352 days</strong></td>
    <td>KRAS mutated unresectable locally advanced or metastatic NSCLC PDAC and CRC</td>
    <td>Biomea Fusion Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_25">Study Arms</button></td>
    <td>BMF-219</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05631574" target="_blank">NCT05631574</a></td><td><select class="form-select" id="select_form_36" name="NCT05631574"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting</strong></td>
    <td>Locally advanced or metastatic solid tumors</td>
    <td>Asher Biotherapeutics Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_26">Study Arms</button></td>
    <td><p>AB248; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_516">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05653882" target="_blank">NCT05653882</a></td><td><select class="form-select" id="select_form_37" name="NCT05653882"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 120 days; Start Date pushed later by 119 days</strong></td>
    <td>Advanced non-small cell lung cancer</td>
    <td>VA Office of Research and Development</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_27">Study Arms</button></td>
    <td>Tazemetostat</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05467748" target="_blank">NCT05467748</a></td><td><select class="form-select" id="select_form_38" name="NCT05467748"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 182 days</strong></td>
    <td>Small-cell Lung Cancer</td>
    <td>Case Comprehensive Cancer Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_28">Study Arms</button></td>
    <td><p>Abemaciclib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04010357" target="_blank">NCT04010357</a></td><td><select class="form-select" id="select_form_39" name="NCT04010357"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 366 days; Primary Completion Date pushed later by 365 days</strong></td>
    <td>Resectable and operable stage IB - III non-small cell lung cancer</td>
    <td>Brown University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_29">Study Arms</button></td>
    <td><p>Ipilimumab; Nivolumab; SBRT</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04933903" target="_blank">NCT04933903</a></td><td><select class="form-select" id="select_form_40" name="NCT04933903"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 731 days; Enrollment increased by: 130</strong></td>
    <td>Metastatic Solid Tumors</td>
    <td>Inhibrx Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_30">Study Arms</button></td>
    <td><p>INBRX-105 - PDL1x41BB antibody; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_517">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03809624" target="_blank">NCT03809624</a></td><td><select class="form-select" id="select_form_41" name="NCT03809624"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 366 days</strong></td>
    <td>Advanced or metastatic melanoma Merkel cell carcinoma renal cell carcinoma or non-small cell lung cancer tumors</td>
    <td>ImaginAb Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_31">Study Arms</button></td>
    <td>zirconium Zr 89 crefmirlimab berdoxam</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05013099" target="_blank">NCT05013099</a></td><td><select class="form-select" id="select_form_42" name="NCT05013099"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 273 days</strong></td>
    <td>Advanced non-small cell lung cancer (NSCLC) with EGFR uncommon mutations</td>
    <td>Zhejiang Cancer Hospital</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_32">Study Arms</button></td>
    <td>sintilimab and anlotinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04790409" target="_blank">NCT04790409</a></td><td><select class="form-select" id="select_form_43" name="NCT04790409"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 184 days; Changed status from recruiting to active; Primary Completion Date pushed later by 304 days</strong></td>
    <td>Locally Advanced or Metastatic NSCLC</td>
    <td>Palobiofarma SL</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_33">Study Arms</button></td>
    <td>PBF-1129</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03274479" target="_blank">NCT03274479</a></td><td><select class="form-select" id="select_form_44" name="NCT03274479"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days; Primary Completion Date pushed later by 731 days</strong></td>
    <td>Stage III Non-small-cell Lung Cancer</td>
    <td>Brown University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_34">Study Arms</button></td>
    <td><p>Durvalumab; SBRT</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03589547" target="_blank">NCT03589547</a></td><td><select class="form-select" id="select_form_45" name="NCT03589547"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date moved earlier by 5329 days; Trial completed; Primary Completion Date pushed later by 138 days</strong></td>
    <td>Sdvanced solid tumors</td>
    <td>Fate Therapeutics</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_35">Study Arms</button></td>
    <td><p>FT516; Avelumab; Cyclophosphamide; Fludarabine; IL-2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_520">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04551885" target="_blank">NCT04551885</a></td><td><select class="form-select" id="select_form_46" name="NCT04551885"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 749 days; Primary Completion Date pushed later by 478 days</strong></td>
    <td>Solid Tumors</td>
    <td>Kirilys Therapeutics Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_36">Study Arms</button></td>
    <td>ASN004</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04410224" target="_blank">NCT04410224</a></td><td><select class="form-select" id="select_form_47" name="NCT04410224"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Primary Completion Date pushed later by 90 days</strong></td>
    <td>High grade serous ovarian cancer and nonsmall cell lung cancer</td>
    <td>Mersana Therapeutics</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_37">Study Arms</button></td>
    <td>XMT-1592</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04396340" target="_blank">NCT04396340</a></td><td><select class="form-select" id="select_form_48" name="NCT04396340"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Changed status from recruiting to active; Primary Completion Date pushed later by 182 days</strong></td>
    <td>Locally-advanced or metastatic solid tumors which harbor the NRG1 gene fusion</td>
    <td>Elevation Oncology</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_38">Study Arms</button></td>
    <td>Seribantumab</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04383210" target="_blank">NCT04383210</a></td><td><select class="form-select" id="select_form_49" name="NCT04383210"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 366 days; Enrollment increased by: 1000; Primary Completion Date pushed later by 732 days; Start Date pushed later by 427 days</strong></td>
    <td>Non-small cell lung cancer (NSCLC) triple negative breast cancer (TNBC) colorectal cancer (CRC) and pancreatic cancer</td>
    <td>Persephone Biosciences</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_39">Study Arms</button></td>
    <td>Immunotherapy; Chemotherapy; CRC surgical resection; Colonoscopy</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04638751" target="_blank">NCT04638751</a></td><td><select class="form-select" id="select_form_50" name="NCT04638751"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Primary Completion Date pushed later by 273 days</strong></td>
    <td>Solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations)</td>
    <td>Seagen Inc.</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_40">Study Arms</button></td>
    <td><p>tucatinib; trastuzumab; fulvestrant</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_524">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04579380" target="_blank">NCT04579380</a></td><td><select class="form-select" id="select_form_51" name="NCT04579380"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 730 days; Primary Completion Date pushed later by 731 days</strong></td>
    <td>Solid Tumors</td>
    <td>Inhibrx Inc.</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_41">Study Arms</button></td>
    <td><p>INBRX-106 - Hexavalent OX40 agonist antibody; Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_524">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04198766" target="_blank">NCT04198766</a></td><td><select class="form-select" id="select_form_52" name="NCT04198766"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Start Date pushed later by 90 days</strong></td>
    <td>Advanced non-small cell lung cancer (NSCLC) ineligible for treatment with curative intent due to 1) disease stage IV or 2) inability to tolerate intensive surgery or chemo-radiation</td>
    <td>Icahn School of Medicine at Mount Sinai</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_42">Study Arms</button></td>
    <td><p>Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_524">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05589818" target="_blank">NCT05589818</a></td><td><select class="form-select" id="select_form_53" name="NCT05589818"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo3" class="accordion-toggle">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo3"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Enrollment increased by: 60</strong></td>
    <td>Advanced or metastatic non-small cell lung cancer (NSCLC)</td>
    <td>Gilead Sciences</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_43">Study Arms</button></td>
    <td><p>Sacituzumab Govitecan-hziy (SG); Docetaxel</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_524">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05089734" target="_blank">NCT05089734</a></td><td><select class="form-select" id="select_form_54" name="NCT05089734"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment decreased by: 27</strong></td>
    <td>Small Cell Lung Cancer</td>
    <td>Amgen</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_44">Study Arms</button></td>
    <td>Tarlatamab; AMG 404</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04885998" target="_blank">NCT04885998</a></td><td><select class="form-select" id="select_form_55" name="NCT04885998"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Enrollment increased by: 45</strong></td>
    <td>Advanced or Metastatic Non-small Cell Lung Cancer</td>
    <td>AstraZeneca</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_45">Study Arms</button></td>
    <td>AZD2936</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04995523" target="_blank">NCT04995523</a></td><td><select class="form-select" id="select_form_56" name="NCT04995523"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Enrollment increased by: 10; Changed status from active to recruiting</strong></td>
    <td>Non-Small-Cell Lung Cancer</td>
    <td>Takeda</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_46">Study Arms</button></td>
    <td>TAK-788</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02716116" target="_blank">NCT02716116</a></td><td><select class="form-select" id="select_form_57" name="NCT02716116"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 92 days</strong></td>
    <td>ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC</td>
    <td>Pfizer</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_47">Study Arms</button></td>
    <td><p>PF-06463922; Crizotinib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_527">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01970865" target="_blank">NCT01970865</a></td><td><select class="form-select" id="select_form_58" name="NCT01970865"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 106 days</strong></td>
    <td>Advanced or metastatic nonsquamous non-small cell lung cancer</td>
    <td>Merck Sharp & Dohme LLC</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_48">Study Arms</button></td>
    <td><p>Pembrolizumab 200 mg; Cisplatin; Carboplatin; Pemetrexed; Folic acid 350-1000 g; Vitamin B12 1000 g; Dexamethasone 4 mg; Saline solution</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_527">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03950674" target="_blank">NCT03950674</a></td><td><select class="form-select" id="select_form_59" name="NCT03950674"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 275 days</strong></td>
    <td>Locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s)</td>
    <td>Boehringer Ingelheim</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_49">Study Arms</button></td>
    <td>afatinib</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT01853826" target="_blank">NCT01853826</a></td><td><select class="form-select" id="select_form_60" name="NCT01853826"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 201 days</strong></td>
    <td>Advanced and/or metastatic solid tumors</td>
    <td>Hoffmann-La Roche</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_50">Study Arms</button></td>
    <td>RO7121661</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03708328" target="_blank">NCT03708328</a></td><td><select class="form-select" id="select_form_61" name="NCT03708328"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 299 days</strong></td>
    <td>Non-Small Cell Lung Cancer; Urothelial Carcinoma</td>
    <td>AstraZeneca</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_51">Study Arms</button></td>
    <td><p>Durvalumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_529">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05303532" target="_blank">NCT05303532</a></td><td><select class="form-select" id="select_form_62" name="NCT05303532"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 170 days; Enrollment decreased by: 156</strong></td>
    <td>Advanced solid tumors</td>
    <td>AstraZeneca</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_52">Study Arms</button></td>
    <td><p>AZD5305; Paclitaxel; Carboplatin; T- Dxd; Dato-DXd</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_529">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04644068" target="_blank">NCT04644068</a></td><td><select class="form-select" id="select_form_63" name="NCT04644068"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Start Date pushed later by 92 days</strong></td>
    <td>Metastatic ALK+ Non Small Cell Lung Cancer</td>
    <td>Pfizer</td>
<td><p>N/A</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_53">Study Arms</button></td>
    <td>Lorviqua</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05599412" target="_blank">NCT05599412</a></td><td><select class="form-select" id="select_form_64" name="NCT05599412"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_11" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Brigatinib until progressive disease unacceptable toxicity withdrawal of consent. Patients enrolled regardless the number of lines of therapy|Brigatinib until progressive disease unacceptable toxicity withdrawal of consent. Patients enrolled after first-line alectinib|Brigatinib at 240 mg daily until progressive disease unacceptable toxicity withdrawal of consent. Patients enrolled after treatment on brigatinib at the standard dose brigatinib</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: brigatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>"An assessment of the response using RECIST 1.1 per investigator. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR) Disappearance of all target lesions; Partial Response (PR) =30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR."". The enrollment in the clinical trial did not reach the target number of subjects needed to achieve target power and was insufficient to produce statistically reliable results"</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through study completion (average 42 months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_12" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>For the Phase 1:||Avelumab is administered intravenously (IV) on Day 1 and Day 15 of each Cycle (one cycle = 28 days) in combination with axitinib po bid and palbociclib po (7 days off; 21 days on).||For the Phase 2:||Avelumab axitinib and palbociclib are administered at the recommended dose (RP2D) as determined during the phase 1 part of the study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Palbociclib; Drug: Axitinib; Drug: Avelumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose Limiting Toxicity (DLT)|Incidence of the tested 3-Drug Combination Therapy-Emergent Adverse Events and Serious Adverse Events|Response Rate (RR)|Duration of the Response|Progression-Free Survival (PFS)|Overall Survival (OS)|SIMS Algorithm to Predict Clinical Outcome</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Progression Free Survival (PFS) is defined as the time from the first dose of study treatment to the date of disease progression by RECIST 1.1 or death due to any cause whichever occurs first.; OS is defined as the time from the first dose of study treatment to the date of death due to any cause.; Response rate is defined as the proportion of participants with reduction in tumor burden of a predefined amount based on RECIST 1.1 evaluation; The occurrence of adverse events and serious adverse events reported from the signing of an informed consent through 90 days after the last administration of the treatment will be summarized for all subjects who received at least one dose of the study treatment (safety population) and will be evaluated based on NCI CTCAE v4.03: June 14 2010.; The proportion of participants whose SIMS analysis matches the treatment combination will be correlated retrospectively to clinical outcome.; Duration of Response (DR) is defined for patients with confirmed objective response (Complete Response [CR] or Partial Response [PR]) as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause whichever occurs first.; DLT is assessed by NCI CTCAE v4.03</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline up to approximately 24 months; From informed consent signature through 90 days after administration of the treatment (last dose); 4 years; Cycle 1 Days 1-28 (28 days from date of first dose of study treatment)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_13" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>ADV/HSV-tk (5 x 1011 virus particles) in a 2-mL total volume will be injected intratumorally on Day 0.||Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days from Day 1 to Day 15.||SBRT of 30 Gy (6 Gy X 5 fractions) will be administered over 2 weeks from Day 2 to Day 16.||Pembrolizumab (200 mg) will be administered intravenously over 30 minutes every 3 weeks starting on Day 17 and continuing until disease progression unacceptable toxicity or up to 24 months in patients without disease progression.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: SBRT; Drug: Valacyclovir; Drug: Pembrolizumab; Biological: ADV/HSV-tk</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The objective response rate (ORR) of ADV/HSV-tk plus (+) valacyclovir therapy in combination with SBRT used as a window of opportunity treatment before pembrolizumab in patients with metastatic TNBC and metastatic NSCLC. Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be used to assess treatment response. Modified immune-related response criteria (irRC; derived from RECIST 1.1) will also be documented.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>30 days after the last dose of pembrolizumab until disease progression initiating a non-study cancer treatment withdrawing consent or becoming lost to follow-up. Median duration of follow-up was 8.3 months (95% CI 3.0-10.1 months).</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_14" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose Escalation Phase will group all disease indications (NSCLC PDAC and CRC) together to assess the safety of each dose level.||Participants will receive escalating dose BMF-219 orally once per day or twice per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose).|Dose Expansion Phase will enroll additional subjects independently in each disease indication:||Cohort 1: Participants with NSCLC||Cohort 2: Participants with PDAC||Cohort 3: Patients with CRC||Cohorts 1 2 and 3 will receive BMF-219 at the OBD/ RP2D to further assess the safety and efficacy of the investigational drug.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BMF-219</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable locally advanced or metastatic NSCLC PDAC and CRC.|To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable locally advanced or metastatic NSCLC PDAC and CRC.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>OBD/RP2D as measured by objective response rate (ORR). ORR will be assessed using RECIST 1.1 per investigator assessment.; OBD/RP2D as determined by the number of subjects receiving BMF-219 monotherapy who experience Dose-Limiting Toxicities (DLTs) within each dose level. A DLT is defined as any clinically significant Adverse Event within 28 days of starting BMF-219 treatment and considered to be related to the IMP. Adverse Events will be assessed per CTCAE v5.0.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>30 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_15" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Avelumab; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: FT516; Drug: IL-2</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of dose-limiting toxicities within each dose level cohort|Nature of dose-limiting toxicities within each dose level cohort</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At the end of Cycle 1 (each cycle is 28 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_16" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The treatment will consist of one dose of avelumab every other week as well as a short course of SBRT after the first two doses of avelumab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Avelumab; Radiation: Stereotactic Body Radiation Therapy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall response rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>defined by modified RECIST 1.1 for mesothelioma</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_17" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Induction phase: atezolizumab will be given intravenously (iv) at a dose of 1200 mg for 60 minutes on day 1 of each cycle. Subsequent atezolizumab cycles may be administered for 30 minutes if there were no perfusion-related toxicity. Pemetrexed will be administered at a dose of 500 mg/m2 IV for 15 minutes on day 1 of each cycle. In addition folic acid vitamin B12 and dexamethasone 4 mg will be given the day before and the day after treatment with pemetrexed. Carboplatin will be given at a dose with an area under the 5 curve for 30 minutes on day 1 of each cycle approximately 30 minutes after the pemetrexed infusion is complete. After completing 4 to 6 cycles of Carboplatino plus pemetrexed and atezolizumab patients will continue with pemetrexed in combination with atezolizumab (maintenance phase) until they have an unacceptable toxicity progression of the disease decision of the patient/physician or have Completed 2 years of treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Atezolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Efficacy of atezolizumab + CBDCA + pemetrexed by evaluating PFS</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To evaluate the efficacy of Atezolizumab in terms of rate of progression free survival after enrollment defined as the sate of patients free of disease progressionor death from any cause wichever occurs first at 12 weeks as determined by the investigator according to RANO and RECIST v1.1 criteria for brain and Systemix disease respectively.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>12 weeks after enrollment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_18" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients will receive certolizumab with 6 cycles of cisplatin & pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation second dose will be given after 2 weeks of treatment third dose after four weeks of treatment & subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested 200mg & 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: cisplatin; Drug: Certolizumab; Drug: pemetrexed</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated does (MTD)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>A standard 3+3 dose-escalation scheme will be used to test two doses of certolizumab: dose level A (200mg) and dose level B (400mg) in combination with the standard dose of chemotherapy. In addition two de-escalation doses are planned if dose level A proves too toxic: dose level C (chemotherapy at 75% of the standard dose + certolizumab 200mg) and dose level D (chemotherapy at 75% of the standard dose + certolizumab 400mg)..The MTD is the highest dose at which ≤ 1/6 patients experiences a DLT. Please see the dose escalation schema for exact dose level details.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_19" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients within this arm will undergo a high-resolution CT scan of the chest which is required by Synapse 3D to create accurate 3D virtual model reconstructions. At the start of the operation the 3D virtual model of the segmental pulmonary anatomy will be displayed on the da Vinci Robotic platform for operative planning. The model will be used as a guide to determine which vessels are involved in the segment and need to be removed. The surgeon will ligate the pulmonary vein and pulmonary artery of the broncho-pulmonary segment with the lung cancer nodule isolating it from any blood supply and mark the proposed segmental planes based on the 3D model. ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation an 8 mL bolus of ICG solution will be injected into the peripheral vein catheter followed by a 10 mL saline solution bolus</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Device: Synapse 3D Lung Modelling; Drug: IC-Green (ICG)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Segmental Resection Conversion Rate|Number of Participants with Post Operative Complications</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Rate of conversions to lobectomy will be measured by collecting the proportion of conversions to lobectomy.; Post operative complications will be reported and measured using the Ottawa Thoracic Morbidity and Mortality Classification of (a) Adverse reactions to ICG dye at the time of surgery and (b) Perioperative complications through study completion.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_20" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants with Solid Tumors will receive various doses of ABBV-927 by intravenous (IV) infusion plus ABBV-368. This will determine the recommended phase two dose (RP2D) of ABBV-927.|Participants with non-small-cell-lung-cancer (NSCLC) will receive ABBV-927 IV at various dose levels + ABBV-368 + ABBV-181. This will determine the recommended phase two dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181.|Participants with Triple Negative Breast Cancer (TNBC) will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-368 by IV.|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-181 by IV.|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin by IV.|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Nab-paclitaxel + ABBV-368 by IV.|Participants with NSCLC will receive ABBV-927 (at the RP2D established in Arm B) + ABBV-368 + ABBV-181 by IV.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: ABBV-927; Drug: Nab-paclitaxel; Drug: Carboplatin; Drug: ABBV-368; Drug: ABBV-181</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose Expansion: Objective Response Rate (ORR)|Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368|Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>ORR is defined as the percentage of participants with either complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.; The RP2D of ABBV-927 + ABBV-368 will be determined during the dose-escalation phase of the study. RP2D will be determined using available safety and pharmacokinetics data.; The RP2D of ABBV-927 + ABBV-368 + ABBV-181 will be determined during the dose-escalation phase of the study. RP2D will be determined using available safety and pharmacokinetics data.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 6 months; Up to approximately 2 years following the first dose of study drug</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_21" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>TH1902 peptide-drug conjugate</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: TH1902</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Maximum tolerated dose (MTD) of TH1902.|Recommended Phase 2 Dose (RP2D) of TH1902.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The RP2D will be determined following the determination of the MTD and an overall assessment of safety as determined by the Safety Committee.; The MTD will be defined as the dose level at which no more than one of six patients experiences a dose limiting toxicity (DLT) after 21 days of treatment have occurred with the next higher dose having at least 2 of 3 or 2 of 6 patients experiencing a DLT.; Toxicities will be assessed in each patient by tracking the occurrence of graded Adverse Events (AEs). AEs will be graded according to the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) v5.0.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 24 months; Through completion an average of 12 weeks; Up to 21 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_22" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>FT500 administered once weekly for 3 weeks as a monotherapy|FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab pembrolizumab or atezolizumab.|FT500 + IL-2 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab pembrolizumab or atezolizumab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab; Drug: Fludarabine; Drug: IL-2; Drug: Pembrolizumab; Drug: Cyclophosphamide; Drug: Atezolizumab; Drug: FT500</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>The incidence of subjects with Dose Limiting Toxicities within each dose level cohort.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The incidence of subjects with DLTs within each assessed dose level cohort to determine the MTD or MAD.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Day 29</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_23" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>SGN-CD228A monotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: SGN-CD228A</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with adverse events|Number of participants with laboratory abnormalities|Number of participants with dose limiting toxicities</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 3.5 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_24" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive Me-4FDG tracer IV and then undergo PET/CT over 15 minutes.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Laboratory Biomarker Analysis; Procedure: Positron Emission Tomography; Drug: Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside; Procedure: Computed Tomography</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Sensitivity of Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me-4FDG) positron-emission tomography (PET) scans|Specificity of Me-4FDG for lung cancer|Optimal combination of sensitivity and specificity|Incidence of adverse events of Me-4FDG|Efficacy of Me-4FDG in diagnosing lung cancer</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will be determined by calculating the standardized uptake value (SUV) in the lesions and the contrast to noise ratio (CNR) relative to an area of normal lung surrounding the lesion and evaluated by assessing the percentage of patients with a pathologic diagnosis of lung cancer that results positive at Me-4FDG PET scans.; Will tabulate the number of adverse events (AEs) and the severity of adverse events (SAEs) for the overall population as well as within subjects.; Will be evaluated by measuring the percentage of test positivity in patients with a pathological diagnosis of lung cancer.; Will be estimated by the percentage of Me-4FDG negativity in lung nodules that have been determined radiologically and/or clinically to be benign with a lung-RAD (Lung Imaging Reporting and Data System) score 1-3.; Will combine SUV and CNR cut-points that yield the optimal combination of sensitivity (positivity within the adenocarcinoma group) and specificity (negativity with the benign group). Optimality will be based on the cut-points that maximize the Youden index (sum of the sensitivity plus specificity). Based on the combined cut point will construct 95% confidence intervals for the sensitivity and specificity.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From baseline to one week after Me-4FDG administration; within one week of the experimental PET/CT scan; within one month of surgery or biopsy; within one week of experimental PET/CT scan</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_25" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Dose Escalation Phase will group all disease indications (NSCLC PDAC and CRC) together to assess the safety of each dose level.||Participants will receive escalating dose BMF-219 orally once per day or twice per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose).|Dose Expansion Phase will enroll additional subjects independently in each disease indication:||Cohort 1: Participants with NSCLC||Cohort 2: Participants with PDAC||Cohort 3: Patients with CRC||Cohorts 1 2 and 3 will receive BMF-219 at the OBD/ RP2D to further assess the safety and efficacy of the investigational drug.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: BMF-219</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable locally advanced or metastatic NSCLC PDAC and CRC.|To determine the OBDs/RP2Ds of BMF-219 monotherapy in subjects with KRAS-driven unresectable locally advanced or metastatic NSCLC PDAC and CRC.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>OBD/RP2D as measured by objective response rate (ORR). ORR will be assessed using RECIST 1.1 per investigator assessment.; OBD/RP2D as determined by the number of subjects receiving BMF-219 monotherapy who experience Dose-Limiting Toxicities (DLTs) within each dose level. A DLT is defined as any clinically significant Adverse Event within 28 days of starting BMF-219 treatment and considered to be related to the IMP. Adverse Events will be assessed per CTCAE v5.0.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>30 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_26" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>AB248 will be administered intravenously as a single agent|AB248 and pembrolizumab will be administered intravenously|AB248 will be administered intravenously as a single agent in disease specific cohorts|AB248 and pembrolizumab will be administered intravenously in disease specific cohorts</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Pembrolizumab; Biological: AB248</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Frequency of Dose-Limiting Toxicities (DLTs)|Frequency of Serious Adverse Events (SAEs)|Frequency of Treatment Emergent Adverse Events (TEAEs)|Frequency of Adverse Events of Special Interest (AESIs)|Frequency of Adverse Events (AEs) leading to dose interruption or treatment discontinuation and death</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Based on toxicities observed</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Signed consent up to 90 days after discontinuing study treatment; Study Day 1 up to 90 days after discontinuing study treatment; From Study Day 1 through up to Day 21</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_27" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Enrolled patients will receive combination treatment for whole study duration (2 years). For first cycle patient will start tazemetostat one week prior to start every 3 week pembrolizumab intravenous infusion (pembrolizumab will be given day 8 only for the first cycle rest of cycles will be day 1 of each cycle).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Tazemetostat</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate (ORR)|Safety and Tolerability</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Safety and tolerability assessed by CTCAE v5.0; ORR assessed by RECIST v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_28" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Subjects will receive Abemaciclib (200 mg) orally every 12 hours on days 1 to 28 of a 28-day cycle for a total of 56 doses per cycle.|Subjects will be evaluated after 4 weeks (1st cycle) and then every 8 weeks (2 cycles) with radiographic imaging to assess response to treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Abemaciclib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to  10 mm.; PR: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.; Overall Response Rate (ORR) defined as the proportion of subjects in the analysis population who have complete response (CR) or partial response (PR) using RECIST 1.1 criteria at any time during the study. Response for the primary analyses will be determined by independent radiology review.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years from start of study</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_29" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Ipilimumab: 1mg/kg IV day 1. Nivolumab: 3mg/kg IV days 1 15 29. SBRT delivered as 1-2 fractions to the gross primary tumor and nodal disease following day 1 infusion and completed by day 3 (7Gy x 1; 4Gy x 2).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab; Drug: Ipilimumab; Radiation: SBRT</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Patients with a Pathologic Response</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Assess Pathologic Response (major pathologic response and complete pathologic response) following neoadjuvant low dose SBRT Ipilimumab and Nivolumab.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From beginning of study treatment to approximately day 49-63 on study.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_30" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>INBRX-105 will be escalated in patients with locally advanced or metastatic solid tumors.|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.|Patients with gastric or gastro-esophageal junction adenocarcinoma renal cell carcinoma and urothelial (transitional) cell carcinoma will be treated with single-agent INBRX-105 at either the MTD or RP2D.|Patients with head and neck squamous cell carcinoma will be treated with single-agent INBRX-105 at either the MTD or RP2D.|INBRX-105 will be escalated in combination with Pembrolizumab in pateitns with locally advanced or metastatic solid tumors.|Patients will be treated with INBRX-105 in combination with Pembrolizumab.|Patients will be treated with INBRX-105 in combination with Pembrolizumab.|Patients with head and neck squamous cell carcinoma gastro-esophageal junction adenocarcinoma renal cell carcinoma and urothelial (transitional) cell carcinoma will be treated with INBRX-105 in combination with Pembrolizumab.|CPI naive patients (PD-L1 IHC between 1 and 49%) will be treated with INBRX-105 in combination with Pembrolizumab.|CPI naive patients (PD-L1 IHC 50%) will be treated with INBRX-105 in combination with Pembrolizumab.|CPI refractory/relapsed CPI patients (PD-L1 IHC 50%) will be treated with INBRX-105 in combination with Pembrolizumab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: INBRX-105 - PDL1x41BB antibody; Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Frequency of adverse events of INBRX-105|Severity of adverse events of INBRX-105|Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-105</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The MTD and/or RP2D of INBRX-105 will be determined.; Severity of adverse events will be assessed and assigned by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.; Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2-3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_31" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Eligible subjects will receive up to three zirconium Zr 89 crefmirlimab berdoxam PET scans (up to 1.0 mCi ± 20% at 1.5 mg API per scan for a total of up to 3.0 mCi ± 20% and 4.5 mg API) as an IV infusion or slow bolus injection as follows: First scan within 14 days prior to the onset of IOT and a second scan 4 to 6 weeks after start of immunotherapy. The second zirconium Zr 89 crefmirlimab berdoxam administration and scan should be completed prior to the start of the third cycle of IOT. Subjects who are determined by the treating physician to have PD on immunotherapy can receive the optional third zirconium Zr 89 crefmirlimab berdoxam PET scan at the principal investigator's (PI's) discretion.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: zirconium Zr 89 crefmirlimab berdoxam</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Best overall response (BOR) assessed by conventional imaging CT and/or MRI using RECIST 1.1 tomography/computed tomography (PET/CT)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Best overall response (BOR) assessed by conventional imaging CT and/or MRI using RECIST 1.1 from 3 (or up to 3) consecutive imaging assessments (CT and/or MRI) following onset of immuno-oncology treatment.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline to at least 24 or 27 weeks after the start of IOT depending on treatment schedule.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_32" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients received sintilimab (anti-PD-1) combined with anlotinib (multi-target anti-angiogenesis).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: sintilimab and anlotinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>objective response rate (ORR) through study completion an average of 1 year</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_33" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: PBF-1129</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum Tolerated Dose (MTD) of PBF-1129</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The MTD evaluation will be based on the Dose-limiting Toxicity (DLT) of the treated Population which includes all subjects who receive any dose of PBF-1129 and will include Adverse events (AEs) Serious Adverse events (SAEs) laboratory evaluations and electrocardiogram (ECG) results</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_34" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Durvalumab 10mg/kg x 1 day dose #1 to occur  3 weeks and 7 weeks after last chemo/RT and prior to SBRT dose 1 (5-10 day time frame between Durvalumab and SBRT).||SBRT boost will consist of 2 fractions delivered to the primary tumor only over 1-2 weeks between the first and second treatments with durvalumab (see above for time frames). The dose will consist of 20Gy (2 fractions of 10Gy). 3 fractions are allowed for centrally located tumors||Dose # 2 of durvalumab (post SBRT) to be given 1-10 days post last SBRT. Durvalumab then to be given at 10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Radiation: SBRT; Drug: Durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of patients experiencing grade 2 or higher toxicities during consolidation SBRT with concurrent durvalumab after chemoradiation for locally advanced stage III NSCLC|Average progression-free survival of chemoradiation followed by SBRT and durvalumab for patients with locally advanced stage III NSCLC.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>This outcome will examine the safety and tolerability of the trial.; RECIST 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Defined as the first 3 months of durvalumab.; Every 3 months for 1 year then every 4 months for two years then every 6 months for two years then annually until progression on average for about 5 years.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_35" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Avelumab; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: FT516; Drug: IL-2</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of dose-limiting toxicities within each dose level cohort|Nature of dose-limiting toxicities within each dose level cohort</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At the end of Cycle 1 (each cycle is 28 days)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_36" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients will receive escalating doses of ASN004 to identify the best dose for further study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: ASN004</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Determine the maximum tolerated dose of ASN004</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The MTD will be determined by evaluating the number of subjects with treatment related adverse events (AEs) and DLTs.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>first 21 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_37" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>XMT-1592 is administered in groups of patients who will receive doses that increase over time until the maximum tolerated dose is achieved.|New groups of patients will receive XMT-1592 at the maximum tolerated dose to confirm the recommended Phase 2 dose</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: XMT-1592</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose or recommended Phase 2 dose</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Evaluate adverse events and use of concomitant medication use after XMT-1592 doses</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 36 weeks from the date of first dose until unacceptable side effects or a dose-limiting toxicity is me</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_38" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>A minimum of 55 adult advanced solid tumor patients harboring NRG1 gene fusions who have received prior standard treatment excluding prior ERBB-directed therapy.||Seribantumab 1-h IV infusion at various doses once weekly every 2 weeks and every 3 weeks during the induction consolidation and maintenance dosing phases respectively.|Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions who have received prior standard treatment including prior ERBB-directed therapy.||Seribantumab 1-h IV infusion at various doses once weekly every 2 weeks and every 3 weeks during the induction consolidation and maintenance dosing phases respectively.|Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions lacking an EGF-like domain who have received prior standard treatment which may have included prior ERBB-directed therapy.||Seribantumab 1-h IV infusion at various doses once weekly every 2 weeks and every 3 weeks during the induction consolidation and maintenance dosing phases respectively.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Seribantumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Objective Response Rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The primary objective of this study is to determine the overall objective response rate (ORR) by independent radiologic review to single agent seribantumab in patients with NRG1 gene fusion positive advanced cancer according to RECIST 1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 12 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_39" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Stage 3 or stage 4 non-small cell lung cancer patients being administered checkpoint inhibitor therapy for the first time. Dosage form dosage frequency and duration will be either standard of care and accessed via normal commissioning arrangements or will be part of an ethics-approved clinical trial where co-enrollment into an observational study is permitted.|Stage 3 or stage 4 metastatic triple-negative breast cancer patients being administered any type of treatment that the patient has not experienced before. Dosage form dosage frequency and duration will be either standard of care and accessed via normal commissioning arrangements or will be part of an ethics-approved clinical trial where co-enrollment into an observational study is permitted.|Stage 3 or stage 4 colorectal cancer patients being administered any type of treatment that the patient has not experienced before. Dosage form dosage frequency and duration will be either standard of care and accessed via normal commissioning arrangements or will be part of an ethics-approved clinical trial where co-enrollment into an observational study is permitted.|Stage 3 or stage 4 pancreatic cancer patients being administered any type of treatment that the patient has not experienced before. Dosage form dosage frequency and duration will be either standard of care and accessed via normal commissioning arrangements or will be part of an ethics-approved clinical trial where co-enrollment into an observational study is permitted.|Subjects undergoing a standard-of-care colonoscopy for colorectal cancer (CRC) screening considered at high risk for CRC due to either 1) one or more first degree relatives with a history of CRC or 2) a personal history of colorectal cancer advanced adenoma as defined by USMSTF guidelines on colorectal cancer or 3 or more non-advanced adenomas in a single screening or surveillance encounter (synchronous).|Subjects undergoing a standard-of-care colonoscopy for colorectal cancer (CRC) screening who are not considered high risk for CRC based on family history or prior colonoscopy findings.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Immunotherapy; Drug: Chemotherapy; Procedure: CRC surgical resection; Procedure: Colonoscopy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Determine whether the microbiome composition can predict progression-free survival|Determine whether the microbiome composition can predict risk for colorectal cancer</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Whole genome sequencing and metabolomics will be used to characterize the patient's microbiome and whether there is any correlation with response to treatment; Whole genome sequencing and metabolomics will be used to characterize the patient's microbiome. High and low risk subjects will be followed for 8 years to determine if any get CRC.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2-8 years; 6-12 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_40" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: tucatinib; Drug: trastuzumab; Drug: fulvestrant</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Confirmed objective response rate (cORR) per investigator assessment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>cORR is defined as the proportion of participants with best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From start of treatment up to approximately 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_41" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.|Subjects with non-small cell lung cancer melanoma head and neck squamous cell carcinoma gastric or gastro-esophageal junction adenocarcinoma renal cell carcinoma and urothelial (transitional) cell carcinoma will be treated with INBRX-106 at the RP2D.|INBRX-106 will be escalated in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors.|Subjects with non-small cell lung cancer melanoma head and neck squamous cell carcinoma gastric or gastro-esophageal junction adenocarcinoma renal cell carcinoma and urothelial (transitional) cell carcinoma will be treated with INBRX-106 at the RP2D in combination with pembrolizumab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: INBRX-106 - Hexavalent OX40 agonist antibody; Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab|Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab|MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0; Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>2-4 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_42" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients will be treated with the standard dose of pembrolizumab (200mg IV every 3 weeks) for the first 12 weeks of the study. After week 12 assessments patients without objective progression of disease are eligible to transition to Q6W dosing of pembrolizumab 400mg IV.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Pembrolizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Change in EORTC QLQ-C30 Quality of Life score</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Change in quality of life (QOL) score at 12 weeks post-treatment compared to baseline with pembrolizumab as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). The scale ranges from 1=very poor to 7 = excellent. The higher the score the better the quality of life.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline and 12 weeks post-treatment</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_43" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle (ie 2 weekly doses plus 1 week without treatment) until progressive disease (PD) death unacceptable toxicity or another treatment discontinuation criterion is met.|Participants will receive docetaxel 75 mg/m^2 on Day 1 of a 21-day cycle (ie once every 3 weeks) until PD death unacceptable toxicity or another treatment discontinuation criterion is met.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Docetaxel; Biological: Sacituzumab Govitecan-hziy (SG)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>OS is defined as the time from the date of randomization until the date of death from any cause.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 30 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_44" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>The recommended phase 2 target dose (RP2D) of tarlatamab in combination with AMG 404 will be estimated using a modified toxicity probability interval (mTPI-2) design. A combination RP2D may be identified based on emerging safety efficacy and pharmacodynamic data prior to reaching an maximum tolerated dose (MTD).|Participants will receive the RP2D of tarlatamab in combination with AMG 404 identified in Phase 1 (dose exploration) of the study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: AMG 404; Drug: Tarlatamab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Participants with a Dose Limiting Toxicity (DLT)|Number of Participants with a Treatment-emergent Adverse Event (TEAE)|Number of Participants with a Treatment-related Adverse Event|Number of Participants with a Clinically Significant Change from Baseline in Vital Signs|Number of Participants with a Clinically Significant Change from Baseline in Electrocardiogram (ECG) Measurements|Number of Participants with a Clinically Significant Change from Baseline in Clinical Laboratory Tests</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>24 months; Baseline to Month 24; 28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_45" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>AZD2936 Intravenous (IV) monotherapy|AZD2936 IV monotherapy|AZD2936 IV monotherapy|AZD2936 IV monotherapy</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: AZD2936</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs) serious AEs (SAEs) dose limiting toxicities (DLTs) vital signs and abnormal laboratory parameters|Rate of AZD2936 discontinuation due to toxicity|Objective Response Rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness.; Percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST v1.1; Percentage of participants with AEs leading to discontinuation of AZD2936</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Part A B C and D: From first dose to the last dose of AZD2936 (an average of 6 months); Part A B C and D: From the time of informed consent until 90 days after the last dose of AZD2936; Part B C and D: From first dose of AZD2936 to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_46" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>TAK-788 treatment for participants with advanced NSCLC.|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions who have either not received or not shown an objective response to an EGFR tyrosine kinase inhibitors (TKI) and who have no active measurable central nervous system (CNS) metastases.|TAK-788 treatment for NSCLC participants with HER2 exon 20 activating insertions or point mutations and no active measurable CNS metastases.|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions or HER2 exon 20 activating insertions or point mutations and active measurable CNS metastases.|TAK-788 treatment for NSCLC participants with other targets against which TAK-788 is active (examples include EGFR exon 19 deletions or exon 21 substitutions [with or without T790M mutations] and other uncommon EGFR activating mutations) without active CNS metastases.|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions who have previously shown an objective response to an EGFR TKI and subsequently progressed without active CNS metastases.|TAK-788 treatment NSCLC participants with EGFR exon 20 activating insertions who have not received prior systemic anticancer treatment for locally advanced or metastatic disease without active CNS metastases|TAK-788 treatment for participants with solid tumors other than NSCLC with EGFR/HER2 mutations against which TAK-788 is active without active CNS metastases.|TAK-788 treatment for participants with previously treated locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 20 insertion mutations.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: TAK-788</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Part 1 Dose Escalation Component: Recommended Phase 2 Dose (RP2D) of Orally Administered TAK-788|Part 2 Expansion Cohorts 1 2 4 5 and 7: Confirmed Objective Response Rate (ORR) Assessed by the Investigator|Part 2 Expansion Cohort 3: Intracranial ORR (iORR) Assessed by Independent Review Committee (IRC)|Part 2 Expansion Cohort 6: Confirmed ORR Assessed by IRC|Part 3 Extension Cohort: Confirmed ORR Assessed by IRC</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Cycle 1 (Cycle length is equal to [=] 28 days); Up to 36 months after first dose</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_47" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental; Other</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>ALK+ NSCLC patients who are treatment naïve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: PF-06463922; Drug: Crizotinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1|Percentage of Participants With Overall and Intracranial Objective Response (Phase 2)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>DLT was defined as any of the following adverse events (AEs) attributable to PF-06463922: (1) hematologic: grade 4 neutropenia for 7 days; febrile neutropenia; grade =3 neutropenic infection; grade =3 thrombocytopenia with bleeding; grade 4 thrombocytopenia; (2) non-hematologic: grade =3 pancreatitis; grade =3 toxicities (excluding grade =3 laboratory abnormalities not requiring dose modifications) persisting after optimal treatment with standard medical therapy; symptomatic grade =3 QTc prolongation or asymptomatic grade =3 prolongation that had been confirmed by repeat testing and re-evaluation by a qualified person and persisted after correction of reversible causes; =20% decrease from baseline in left ventricular ejection fraction (LVEF); (3) other: failure to deliver at least 16 out of the 21 prescribed daily total doses due to toxicities attributable to study drug; failure to restart dosing after 21 days (1 cycle) delay due to toxicities attributable to study drug.; Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Intracranial OR refers to confirmed CR or PR considering only lesions within brain. Results presented here were based on independent central review.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Cycle 1 (21 days); 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_48" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression (up to 35 treatment administrations; up to approximately 2 years).|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurs participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression (up to 35 treatment administrations; up to approximately 2 years).</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Dietary Supplement: Folic acid 350-1000 μg; Dietary Supplement: Vitamin B12 1000 μg; Drug: Dexamethasone 4 mg; Drug: Pemetrexed; Drug: Cisplatin; Biological: Pembrolizumab 200 mg; Drug: Carboplatin; Drug: Saline solution</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging|Overall Survival (OS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause whichever occurred first. Per RECIST 1.1 PD was defined as ≥20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study. In addition to the relative increase of 20% the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. The PFS per RECIST 1.1 is presented.; OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. The OS is presented.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through Database Cutoff Date of 20-May-2019 (Up to approximately 31.2 months)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_49" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients will receive afatinib once daily</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: afatinib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Adverse Events according to Common Terminology Criteria (CTCAE Version 3)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>up to 24 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_50" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>RO7121661 will be administered in treatment cycles once every 2 weeks (Q2W). Dose escalation will be carried out according to a modified continual reassessment method (mCRM) with escalation with overdose control (EWOC) design.|This cohort will comprise participants with checkpoint inhibitor (CPI) experienced second line and beyond metastatic melanoma. The starting dose of RO7121661 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.|This cohort will comprise participants with CPI and platinum experienced second or third line PD-L1 positive non-small cell lung cancer (NSCLC). The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.|This cohort will comprise participants with PD-L1 high cancer immunotherapy (CIT) naïve first line NSCLC. The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.|This cohort will comprise participants with CPI naïve small cell lung cancer (SCLC) with prior failure of progression on or intolerance to standard therapy. The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.|This cohort will comprise participants with CPI-naïve esophageal squamous cell carcinoma (ESCC). The starting dose of RO7121661 for Expansion will be derived from the MTD/RDE and the best dosing schedule determined during Dose Escalation.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: RO7121661</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose Escalation: Number of Participants with a Dose-Limiting Toxicity (DLT)|Dose Escalation: Number of Participants with at Least One Adverse Event Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)|Expansion: Objective Response Rate Assessed According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Expansion: Disease Control Rate Assessed According to RECIST v1.1|Expansion: Duration of Response Assessed According to RECIST v1.1|Expansion: Progression Free Survival Assessed According to RECIST v1.1</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>For Part A (1 cycle is 14 days): From Cycle 1 Day 1 to Cycle 2 Day 7 (up to 35 days); Up to 27 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_51" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive durvalumab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Durvalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Number of participants with serious adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To monitor safety and tolerability of continuous study treatment to patients who continue to benefit at the end of the clinical trial by measuring the primary outcome of Serious Adverse Events (SAEs).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From baseline up to follow up at 90 days after the last dose of study drug.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_52" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>AZD5305 Monotherapy|AZD5305 + Paclitaxel|AZD5305 + Carboplatin with or without Paclitaxel|AZD5305 + T- Dxd|AZD5305 + Dato-DXd</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Dato-DXd; Drug: T- Dxd; Drug: Carboplatin; Drug: Paclitaxel; Drug: AZD5305</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>The number of subjects with adverse events/serious adverse events|The number of subjects with dose-limiting toxicity (DLT) as defined in the protocol.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Number of patients with adverse events and with serious adverse events including abnormal clinical observations abnormal ECG parameters abnormal laboratory assessments and abnormal vital signs that changed from baseline; A DLT is defined as any toxicity that occurs from the first dose of study treatment (either AZD5305 or combination anti-cancer agent) up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation. DLTs occurring outside the DLT window (ie late onset toxicities) may be defined as a DLT after consultation with the sponsor and investigators based on the emerging safety profile.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From time of Informed Consent to 28 days post last dose (approximately 1 year). 40 days post last dose for Module 4; From first dose of study treatment until the end of Cycle 1.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_53" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Lorviqua</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of the adverse events from baseline</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>This is a prospective observational non-interventional multi-center study in which subjects will be administered as part of routine practice at Korean health care centers by accredited physicians.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IT ############ -->
<!-- ############################### -->
<!-- ############################### -->

<h3 id="new_it">NO NEW INTRATUMORAL TRIALS</h3><br>
<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_it">Existing Trials - Intratumoral</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 214 days; Start Date pushed later by 151 days</strong></td>
    <td>Metastatic pancreatic adenocarcinoma</td>
    <td>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_54">Study Arms</button></td>
    <td>Tislelizumab; SX-682</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05604560" target="_blank">NCT05604560</a></td><td><select class="form-select" id="select_form_65" name="NCT05604560"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 1431 days; Enrollment increased by: 28</strong></td>
    <td>Recurrent Glioblastoma</td>
    <td>Midatech Ltd</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_55">Study Arms</button></td>
    <td><p>MTX110; Programmable pump and catheter system; Lomustine</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_531">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05324501" target="_blank">NCT05324501</a></td><td><select class="form-select" id="select_form_66" name="NCT05324501"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 366 days</strong></td>
    <td>Tumors that have grown or come back despite standard therapy</td>
    <td>Children's Hospital Los Angeles</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_56">Study Arms</button></td>
    <td>MEK162</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02285439" target="_blank">NCT02285439</a></td><td><select class="form-select" id="select_form_67" name="NCT02285439"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 184 days; Primary Completion Date pushed later by 330 days</strong></td>
    <td>Recurrent Glioblastoma</td>
    <td>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_57">Study Arms</button></td>
    <td>Anti-LAG-3 Monoclonal Antibody BMS 986016; Anti-PD-1; Pharmacological Study; Laboratory Biomarker Analysis; Anti-CD137</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02658981" target="_blank">NCT02658981</a></td><td><select class="form-select" id="select_form_68" name="NCT02658981"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Start Date pushed later by 158 days</strong></td>
    <td>Micro satellite-stable (MSS) colorectal or gastroesophageal cancer metastatic to liver or advanced ovarian cancer</td>
    <td>ImmVirx Pty Ltd</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_58">Study Arms</button></td>
    <td>IVX037</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05427487" target="_blank">NCT05427487</a></td><td><select class="form-select" id="select_form_69" name="NCT05427487"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo4" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo4"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Enrollment decreased by: 20; Trial completed</strong></td>
    <td>Advanced/metastatic solid tumors or lymphomas</td>
    <td>Merck Sharp & Dohme LLC</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_59">Study Arms</button></td>
    <td><p>MK-2118 (IT); MK-2118 (SC); Pembrolizumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_534">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03249792" target="_blank">NCT03249792</a></td><td><select class="form-select" id="select_form_70" name="NCT03249792"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_54" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: SX-682; Drug: Tislelizumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Change in Immune response rate as assessed by density of intratumoral granzyme B+ CD137+ T cells|Pathologic Response Rate as assessed by number of patients with a grade 0-2 pathologic response</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The number of patients with a grade 0-2 pathologic response as defined by the College of American Pathologists (CAP) tumor regression grading system.; The change in density of intratumoral granzyme B+ CD137+ T cells before and after neoadjuvant treatment with tislelizumab and SX-682.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Baseline and 2 weeks; 4 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_55" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Device: Programmable pump and catheter system; Drug: Lomustine; Drug: MTX110</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>The frequency and nature of adverse events serious adverse events and dose limiting toxicities (DLTs) [Safety of MTX110 administered by CED alone and in combination with lomustine]|To determine the recommended Phase 2 dose (RP2D) of MTX110 alone and in combination with lomustine</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td></td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Through study completion an expected average of 16 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_56" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients with non-hematologic malignancies that are recurrent progressive or refractory after standard up-front therapy receiving MEK162 will define the MTD DLT and toxicity profile.|Children with recurrent tumors signaling through the Ras/Raf pathway will be treated in 3 strata to define the activity of MEK162. S1: Children with LGG characterized by a BRAF truncated fusion (KIAA1549 and similar translocations). S2: Children with NF1 and LGG. S 3: Children with tumors involving the Ras/Raf pathway not included in strata 1 or 2.|Patients eligible for phase 2 (any stratum) for whom tumor biopsy or resection is clinically indicated may be enrolled on the target validation arm. Patients will receive MEK162 for 7 to 21 days prior to their surgery. Tumor sample will be analyzed for drug concentration and target inhibition.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: MEK162</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Response rate</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Phase 2: Response rate (strata 1 and 2)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Study duration (up to 3 years)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_57" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive Anti-LAG-3 monoclonal antibody BMS-986016 IV over 60 minutes and on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.||Pharmacological Study||Laboratory Biomarker Analysis|Patients receive Anti-CD137 (Urelumab) IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity||Pharmacological Study||Laboratory Biomarker Analysis|Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes and anti-LAG-3 monoclonal antibody BMS-986016 IV on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.||Pharmacological Study||Laboratory Biomarker Analysis|Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes on days 1 and 15 and Anti-CD137 (urelumab) IV on day 1. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.||(2pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)||Pharmacological Study||Laboratory Biomarker Analysis|Patients pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 (Arm A1) or urelumab (Arm A2) or nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B (B1)) or nivolumab and urelumab as in Part B (B2). Within 45 days of surgical resection patients post-operatively receive drug from one of the four arms.||(3pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Laboratory Biomarker Analysis; Biological: Anti-PD-1; Biological: Anti-LAG-3 Monoclonal Antibody BMS 986016; Biological: Anti-CD137; Other: Pharmacological Study</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose (MTD) of anti-LAG-3 monoclonal antibody BMS-986016 as monotherapy as determined by frequency of toxicity|Maximum tolerated dose (MTD) of anti-CD137 as monotherapy as determined by frequency of toxicity|MTD of Anti-LAG-3 + Anti-PD-1 as determined by frequency of toxicity|MTD of Anti-CD137 + Anti-PD-1 as determined by frequency of toxicity</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The frequency of toxicity will be tabulated by the tested dose or doses using descriptive statistics. The proportion of subjects who experienced grade 3 or above toxicities (as defined by CTCAE v. 5.0 [Common Terminology Criteria for Adverse Events]) will be estimated along with 95% confidence interval. MTD will be confirmed as the maximum dose level at which ≤ 33% of participants experience a dose-limiting toxicity (DLT).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>4 weeks</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_58" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>IVX037 administered intratumorally 1 2 or 3 doses q2wks Day 1 15 and 29 of Cycle 1.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: IVX037</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of dose-limiting toxicities</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Assess the feasibility safety and tolerability of intratumoral IVX037 when administered to patients with advanced colorectal ovarian or gastric cancers.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>21 days after following cessation of study intervention</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_59" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receive MK-2118 via IT injection once weekly (Q1W) on Days 1 8 and 15 of Cycles 1-3 followed by MK-2118 via IT injection once every 3 weeks (Q3W) on Day 1 of Cycle 4 and beyond for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.|Participants receive pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1 8 and 15 of Cycles 1-3 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 4 and beyond for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1 8 and 15 of Cycles 1-2 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 3 and beyond for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.|Participants receive MK-2118 monotherapy via subcutaneous (SC) injection Q1W on Cycle 1 Days 1 and 8 followed by MK-2118 SC injection Q1W on Cycles 2-4 Days 1 8 and 15 for a total of up to 36 cycles (approximately 2 years) plus pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for up to 36 cycles (approximately 2 years). Cycle 1 is 2 weeks long and Cycles 2 and beyond are 3 weeks long.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: MK-2118 (IT); Biological: Pembrolizumab; Drug: MK-2118 (SC)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Dose-limiting Toxicities (DLTs)|Adverse Events (AEs)|Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>An AE is any untoward medical occurrence in a participant temporally associated with the use of study treatment whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented.; An AE is any untoward medical occurrence in a participant temporally associated with the use of study treatment whether or not considered related to the study treatment. The number of participants who experience at least one AE will be reported.; A DLT is defined as the following toxicities if related to study treatment: Grade 4 nonhematologic toxicity; Grade 4 hematologic toxicity lasting ≥7 days except thrombocytopenia (Grade 4 thrombocytopenia of any duration Grade 3 thrombocytopenia with clinically significant bleeding); Non-hematologic adverse event (AE) ≥Grade 3 (with exceptions); Grade 3 or Grade 4 nonhematologic abnormality; Febrile neutropenia Grade 3 or 4; Any toxicity causing treatment discontinuation or causing participant to miss ≥1 dose during the DLT period; Any toxicity that causes a 2 week delay initiating Cycle 2 of pembrolizumab; Any elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value that is ≥3× upper limit of normal (ULN) & an elevated total bilirubin value that is ≥2× ULN & an alkaline phosphatase value that is 2× ULN with no alternative explanation; Any ≥Grade 2 immune-mediated uveitis; Grade 5 toxicity. The number of participants who experience a DLT will be presented.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to approximately 27 months; Arms 1 2 & 3: Cycle 1 (Up to 21 days); Arm 4: Cycles 1 & 2 (Up to 35 days); Up to approximately 31 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW  CT ########### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_ct">New Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Locally advanced or metastatic ER+/HER2- breast cancer</td>
    <td>Sermonix Pharmaceuticals Inc.</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_60">Study Arms</button></td>
    <td><p>Lasofoxifene in combination with abemaciclib; Fulvestrant in combination with abemaciclib</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_534">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05696626" target="_blank">NCT05696626</a></td><td><select class="form-select" id="select_form_71" name="NCT05696626"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo5" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_60" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.|Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Lasofoxifene in combination with abemaciclib; Drug: Fulvestrant in combination with abemaciclib</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Progression free survival (PFS)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>PFS is defined as the time from the date of randomization [Visit 0 (Day 1)] to the earliest date of first documented progression or death due to any cause.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Within approximately 3 years</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING CT ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ct">Existing Trials - Cytotoxic</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date moved earlier by 1390 days; Enrollment decreased by: 70; Trial completed; Primary Completion Date moved earlier by 1058 days</strong></td>
    <td>Myeloid malignancies</td>
    <td>Roswell Park Cancer Institute</td>
<td><p>Phase 4</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_61">Study Arms</button></td>
    <td>Trivalent Influenza Vaccine</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04484532" target="_blank">NCT04484532</a></td><td><select class="form-select" id="select_form_72" name="NCT04484532"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Now recruiting; Start Date pushed later by 151 days</strong></td>
    <td>Circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II III or IV</td>
    <td>Enterome</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_62">Study Arms</button></td>
    <td>EO2040</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05350501" target="_blank">NCT05350501</a></td><td><select class="form-select" id="select_form_73" name="NCT05350501"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Liver cancer that has spread to nearby tissue or lymph nodes (locally advanced) has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable)</td>
    <td>Academic and Community Cancer Research United</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_63">Study Arms</button></td>
    <td><p>Ipilimumab; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_537">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05199285" target="_blank">NCT05199285</a></td><td><select class="form-select" id="select_form_74" name="NCT05199285"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 365 days</strong></td>
    <td>Acute myeloid leukemia</td>
    <td>M.D. Anderson Cancer Center</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_64">Study Arms</button></td>
    <td><p>Azacitidine; Ipilimumab; Laboratory Biomarker Analysis; Nivolumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_537">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT02397720" target="_blank">NCT02397720</a></td><td><select class="form-select" id="select_form_75" name="NCT02397720"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td><strong>Completion Date pushed later by 182 days; Start Date pushed later by 182 days</strong></td>
    <td>Stage II-IV ovarian fallopian tube or primary peritoneal cancer</td>
    <td>Roswell Park Cancer Institute</td>
<td><p>Phase 1|Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_65">Study Arms</button></td>
    <td>Alpha-type-1 Polarized Dendritic Cells; Autologous Natural Killer Cell-like CTLs</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03735589" target="_blank">NCT03735589</a></td><td><select class="form-select" id="select_form_76" name="NCT03735589"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Start Date pushed later by 90 days</strong></td>
    <td>Colorectal Cancer</td>
    <td>Weill Medical College of Cornell University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_66">Study Arms</button></td>
    <td>Botensilimab; Balstilimab</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05571293" target="_blank">NCT05571293</a></td><td><select class="form-select" id="select_form_77" name="NCT05571293"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo6" class="accordion-toggle">  <td colspan="7">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_61" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Within 14 days of baseline influenza titer patients receive trivalent influenza vaccine IM on day 0 (patients in cohorts 1 and 5 receive the vaccine at any time patients in cohorts 2 and 3 receive the vaccine between days 14-25 of hypomethylating agent therapy course and patients in cohort 4 receive the vaccine between days 21-365 from onset of cytotoxic chemotherapy). Patients then undergo titer assessment at days 25-90 and days 115-185.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Trivalent Influenza Vaccine</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Antibody response (by microneutralization assay) to influenza vaccination</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The geometric mean (GMT) and standard deviation of antibody titers will be calculated by cohort at the baseline assessment and 1-3 months post vaccination time points. Antibody response is assessed using the outcome measures: seroprotection seroconversion and GMT. Seroprotection is defined as an hemagglutination inhibition (HAI) titer = 1:40 of each individual influenza antigen. Seroconversion is defined as = 4-fold increase in post-vaccination titer of each individual influenza antigen. The seroprotection and seroconversion rates will be reported by age strata cohort and time-point (1-3 months and 4-6 months post vaccination) using 95% confidence intervals obtained using Jeffrey's prior method. The GMT at each time-point will be compared using one-sided permutation T-tests about the log-transformed data. The GMT ratio (GMTR) between 1-3 months post vaccination and baseline will also be calculated and reported by cohort using a 95% confidence interval.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 4-6 months post-vaccination</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_62" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients With Circulating Tumor DNA-defined Minimal Residual Disease of Colorectal Cancer Stage II III or IV After Completion of Curative Therapy</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: EO2040</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Response to treatment at 6 months</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Percentage of patients with ctDNA clearance and no radiographic evidence of recurrence</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_63" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Ipilimumab; Biological: Nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Confirmed objective response rate (ORR)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>A confirmed response is defined to be either a complete response (CR) or partial response (PR) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Disease status will be assessed using response evaluation criteria in solid tumors (RECIST) version (v.) 1.1 criteria. Overall Response Rate (ORR) is defined as the proportion of evaluable patients who achieve confirmed response (CR or PR) while on treatment. The final ORR point estimate and corresponding 95% confidence interval will be reported according to the method of Clopper-Pearson.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 6 months</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_64" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.|Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Other: Laboratory Biomarker Analysis; Biological: Ipilimumab; Drug: Azacitidine; Biological: Nivolumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Maximum tolerated dose of nivolumab with dihydro-5-azacytidine based on the incidence of dose limiting toxicity assessed by the Common Terminology Criteria for Adverse Events (CTCAE) (Lead-in phase)|Efficacy as measured by the overall response rate defined as complete response + complete response with incomplete platelet recovery + complete response with incomplete count recovery + partial response + marrow clearance of blasts (Phase II)|Incidence of adverse events graded according to CTCAE</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>The maximum tolerated dose is defined as the highest dose level with  2 out of 6 patients experiencing a dose limiting toxicity during the first 28 days of treatment.; Toxicity type severity and attribution will be summarized for each patient using frequency tables.; Will be presented along with 95% confidence interval. The association between overall response rate and patient's clinical characteristics will be examined by Wilcoxon's rank sum test or Fisher's exact test as appropriate.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Within 3 months of treatment initiation; Up to 28 days</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_65" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Patients receive the alpha-type-1 polarized dendritic cell vaccine ID 2 weeks before day 0 on day 0 and on day 28. Patients also receive aDC1 IP over 3-10 seconds on day 0. In the absence of unacceptable side effects patients may receive the alpha-type-1 polarized dendritic cell vaccine every 1-3 months at the discretion of the physician.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: Autologous Natural Killer Cell-like CTLs; Biological: Alpha-type-1 Polarized Dendritic Cells</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events as assessed by Cancer Therapy Evaluation Program (CTEP) version 4 of the Common Terminology Criteria for Adverse Events (CTCAE)|Dose-limiting toxicities (DLT) assessed by CTCAE version 5|Change in immune response|Persistence of nCTLs after their adoptive transfer</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will be used in the estimation of the maximum tolerated dose (MTD) and the accompanying of the dose escalation decisions. However no formal analyses of DLTs are planned.; At day 0 will obtain peritoneal material (outflow and washes) directly before i.p. infusion of nCTLs as well as day 2 (48 hours +/- 24 hours) day 7 (+/- 2 days) 2 weeks (14 days +/- 2 days) and 4 weeks (28 days +/- 3 days) later.; Change in immune response will be measured by the increase in the number of CD3+CD8+NKG2D (high) natural killer cell-like cytotoxic T-lymphocyte (CTLs) (nCTLs) and the increase in total CD3+CD8+ CTLs recovered in the peritoneal washes with evaluation on day 0 versus day 2. The analysis will consist of an analysis-of-covariance (ANCOVA) for the outcome of post-pre ACT treatment cell count with a factor for dose and sampling time 48 hrs +/- 24 hrs.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 4 weeks; Up to 12 months; Up to 14 days after intraperitoneal (IP) infusion of nCTLs; From baseline (day 0) to day 2 (48 hours after adoptive cell therapy [ACT]) administration</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_66" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Botensilimab and balstilimab are both monoclonal antibodies that are administered intravenously. A single dose of botensilimab (75 mg IV) and two doses of balstilimab (240 mg IV) will be administered on the same day. A second dose of balstilimab (240 mg IV) will be administered 14 days later (-2 +5 days). Surgical resection will occur 1-6 weeks following the second dose of balstilimab.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Botensilimab; Drug: Balstilimab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Pathological overall response (pOR) rate determined by analysis of tissue resected during surgery|Number of Adverse Events|Number of Serious Adverse Events|Number of complications leading to delays of 12 weeks or more in surgery after initiation of treatment</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Safety will be assessed by evaluation of the number of SAEs according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 at 90 days post-the last dose of study drug; Resected tumors will be examined in their entirety and regression of resected tumors was assessed by estimating the percentage of residual viable tumor of the macroscopically identifiable tumor bed as identified on routine hematoxylin and eosin (H&E) staining. In addition regression will be classified using the Mandard tumor regression grading system. Major pathologic response (MPR) will be defined as ≤10% of residual viable tumor cells (or ≥ 90% response) corresponding to Mandard tumor regression grade 1 (CR) or 2 (near-CR). PR will be defined as at least 50% tumor regression. However considering the lack of consensus on the definition of PR after immunotherapy tumors with 50% and 90% residual viable tumor will be labeled accordingly as '10-50% tumor regression' as per the NICHE study (Chalabi et. al. 2020). When analyzing pMMR responders versus pMMR nonresponders this subgroup will be included in the group of nonresponders.; Safety will be assessed by evaluation of the number of AEs according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 at 90 days post-the last dose of study drug; Any AEs or SAEs that lead to a delay in surgery greater than 12 weeks from treatment initiation (Day 0) will be recorded. If there are ≥ 2 patients out of the first 6 patients or ≥ 4 patients out of the full 12 participants (≥33%) with AEs/SAEs that lead to a delay in surgery beyond 12 weeks from treatment initiation with the exception of COVID-related procedural delays then this combination of botensilimab and balstilimab at these dosages will not be considered feasible in this population.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Day 105; Day 90; Day 30</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ########### NEW IA ############ -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="new_ia">New Trials - Immune Activation</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Relapsed/refractory multiple myeloma</td>
    <td>Nanjing IASO Biotherapeutics Co.Ltd</td>
<td><p>Phase 1</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_67">Study Arms</button></td>
    <td>Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05698303" target="_blank">NCT05698303</a></td><td><select class="form-select" id="select_form_78" name="NCT05698303"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Stage 1-3 adenocarcinoma of the colon with no signs of distant metastases</td>
    <td>The Netherlands Cancer Institute</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_68">Study Arms</button></td>
    <td><p>Nivolumab; Ipilimumab; Celecoxib 200mg; BMS-986253; BMS-986016</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_540">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03026140" target="_blank">NCT03026140</a></td><td><select class="form-select" id="select_form_79" name="NCT03026140"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Actinic Keratosis</td>
    <td>National Cancer Institute (NCI)</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_69">Study Arms</button></td>
    <td><p>Biopsy; Calcipotriene; Fluorouracil</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_541">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05699603" target="_blank">NCT05699603</a></td><td><select class="form-select" id="select_form_80" name="NCT05699603"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo7" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="6">NO LARGE COMPANY TRIALS</td>
  </tr>
  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_67" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>After lymphodepletion CT103A will be administered as a single infusion.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence and severity of adverse events|Incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)|Number of participants with laboratory abnormalities</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>CRS and ICANS will be evaluated according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading.; Number of participants with laboratory abnormalities will be reported.; An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 with the exception of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Up to 2 years after CT103A infusion.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_68" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV)|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV) drug: celecoxib 200 mg daily (oral)|drug: nivolumab 3 mg/kg day 1 and day 15 (IV) drug: BMS-986253 (anti-IL8) 2400mg on day 1 and day 15 (IV)|drug: nivolumab 240mg IV on day 1 and day 15 drug: relatlimab 240mg IV on day 1 and day 15|drug: nivolumab 480mg IV on day 1 and day 29 drug: relatlimab 480mg IV on day 1 and day 29</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab; Drug: BMS-986253; Drug: Celecoxib 200mg; Drug: Ipilimumab; Drug: BMS-986016</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Incidence of adverse events during the treatment and follow-up (safety)|Disease free survival</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>To assess efficacy of neoadjuvant ipilimumab plus nivolumab in terms of disease-free survival; Adverse events will be assessed (according to CTCAE v4.0) during treatment and follow-up.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>until 100 days after last patient last study drug treatment; until 5 years after diagnosis</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_69" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants receive calcipotriene plus fluorouracil cream topically BID for 6 consecutive days on study. Participants also undergo skin biopsies throughout the study.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Fluorouracil; Drug: Calcipotriene; Procedure: Biopsy</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Induction of CD4+ TRM cells (CD3+CD4+CD103+) in the actinic keratosis</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>Will be assessed at one day after completing one and two courses of calcipotriene plus 5-FU immunotherapy compared with before treatment. Paired t test will be performed to evaluate whether the changes from baseline are significantly different from 0.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>At one day after completing one and two courses of calcipotriene plus 5-FU immunotherapy</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######### EXISTING IA ######### -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="existing_ia">Existing Trials - Immune Activation</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0">
  <thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Completion Date pushed later by 365 days; Primary Completion Date pushed later by 182 days</strong></td>
    <td>Relapsed epithelial ovarian cancer</td>
    <td>Brown University</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_70">Study Arms</button></td>
    <td><p>Nivolumab; Ipilimumab</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_542">See Existing Approval</button></td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03355976" target="_blank">NCT03355976</a></td><td><select class="form-select" id="select_form_81" name="NCT03355976"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo8" class="accordion-toggle" style = "background-color: #E1EBEE;">  <td colspan="7"><button type="button" class="btn btn-large btn-outline-primary">VIEW LARGE COMPANY TRIALS</button></td>
  </tr>
 <tr>  <td colspan="12" class="hiddenRow"> <div class="accordian-body collapse" id="demo8"><table class="table table-striped"><thead>
    <tr>
      <th><h3>Update</h3></th>
      <th><h3>Condition</h3></th>
      <th><h3>Sponsor</h3></th>
      <th><h3>Phase</h3></th>
      <th><h3>Intervention</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td><strong>Now recruiting</strong></td>
    <td>Primary Immune Thrombocytopenia</td>
    <td>Novartis Pharmaceuticals</td>
<td><p>Phase 3</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_71">Study Arms</button></td>
    <td>Ianalumab; Eltrombopag; Placebo</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05653219" target="_blank">NCT05653219</a></td><td><select class="form-select" id="select_form_82" name="NCT05653219"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td><strong>Completion Date pushed later by 91 days</strong></td>
    <td>Chronic Hepatitis B</td>
    <td>GlaxoSmithKline</td>
<td><p>Phase 2</p>    <button type="button" class="btn btn-outline-primary" data-toggle="modal" data-target="#modal_72">Study Arms</button></td>
    <td>GSK3228836; GSK3528869A; Control</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05276297" target="_blank">NCT05276297</a></td><td><select class="form-select" id="select_form_83" name="NCT05276297"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
</div></td></tr>  </tbody>
</table>
<!-- THE MODAL -->
<div class="modal fade" id="modal_70" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Nivolumab 240 mg Day 1 Cycle = 2 weeks|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks|Nivolumab 240 mg Day 1 Cycle = 2 weeks|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Nivolumab; Drug: Ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>RECIST 1.1 and immune mediated RECIST. Confirmatory scans are required. Patients may remain on study post initial progression but are required to be removed from treatment if they progress an additional 10%.</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Every 8 weeks during treatment then every 12 weeks in follow-up for up to 2 years (once off study) and until progression.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_71" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Placebo Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Participants will receive eltrombopag and ianalumab lower dose|Participants will receive eltrombopag and ianalumab higher dose|Participants will receive eltrombopag and placebo</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Drug: Placebo; Drug: Eltrombopag; Biological: Ianalumab</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Time from randomization until treatment failure</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>platelet count below 30 G/L; death; ineligibility to taper or inability to discontinue eltrombopag; need for a rescue treatment; start of a new ITP treatment; Time from randomization until treatment failure is defined as the time from randomization date until the first of the following events indicative of treatment failure:</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>Randomization to until end of study (up to 39 months after randomization of last participant)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- THE MODAL -->
<div class="modal fade" id="modal_72" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Study Arms and Endpoints</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
          </thead>
          <tbody>
            <tr>
          <th colspan="1">Arm Group Type</th>
          <td>Active Comparator; Experimental</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Description</th>
          <td>Eligible participants receive GSK3228836 (Treatment 1) study intervention for 24 weeks of Treatment 1 period followed by GSK3528869A (Treatment 2) study intervention administered at Days 1 57 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week with the possibility to extend up to 12 weeks.|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 24 weeks of Treatment 1 period followed by non-active control (Treatment 2) study intervention administered at Days 1 57 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week with the possibility to extend up to 12 weeks.|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 12 weeks of Treatment 1 period followed by GSK3528869A (Treatment 2) study intervention administered at Days 1 57 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week with the possibility to extend up to 12 weeks.|Eligible participants receive GSK3228836 (Treatment 1) study intervention for 12 weeks of Treatment 1 period followed by non-active control (Treatment 2) study intervention administered at Days 1 57 113 and 169 of Treatment 2 period. The interval between Treatment 1 and Treatment 2 is preferably 1 week with the possibility to extend up to 12 weeks.</td>
            </tr>
            <tr>
          <th colspan="1">Arm Group Intervention</th>
          <td>Biological: GSK3528869A; Drug: Control; Drug: GSK3228836</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Measure</th>
          <td>Percentage of participants reporting any grade 3 adverse event (AE) from first dose of GSK3228836 up to study end|Percentage of participants reporting any serious adverse event (SAE) from first dose of GSK3228836 up to study end|Percentage of participants reporting any adverse events of special interest (AESIs) grade 3 or higher from first dose of GSK3228836 up to study end|Percentage of participants who achieve sustained virologic response (SVR) for 24 weeks after the planned end of active treatment in the absence of rescue medication and difference between treatment arms (corresponding to GSK3228836 regimens)</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Description</th>
          <td>An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding) symptom or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. A grade 3 AE is an AE which prevents normal everyday activities (in adults such an AE would for example prevent attendance at work/school and would necessitate the administration of corrective therapy).; AESI related to GSK3528869A include liver disease-related (LDR) AEs hematological AESI or potential immune-mediated diseases (pIMDs).; AESI related to GSK3228836 treatment include thrombocytopenia alanine transaminase (ALT) increases vascular inflammation and complement activation renal injury or injection site reactions.; An SAE is any untoward medical occurrence that results in death is life-threatening requires hospitalization or prolongation of existing hospitalization results in disability/incapacity is a congenital anomaly/birth defect in the offspring of a study participant or is an abnormal pregnancy outcome.; SVR is defined as Hepatitis B surface antigen (HBsAg) below () lower limit of quantification (LLOQ) and HBV deoxyribose nucleic acid (DNA)  LLOQ.; Rescue medication is defined as any medication initiated for the purpose of antiviral suppression other than the background stable NA therapy irrespective of the reason.; A grade 3 AE is an AE which prevents normal everyday activities (in adults such an AE would for example prevent attendance at work/school and would necessitate the administration of corrective therapy).</td>
            </tr>
            <tr>
          <th colspan="1">Primary Outcome Time Frame</th>
          <td>From first dose of GSK3228836 (Treatment 1 [T1]-Day 1) up to study end (Treatment 2 [T2]-Day 841); From first dose of GSK3228836 (Treatment 1-Day 1) up to study end (Treatment 2-Day 841); For up to 24 weeks after the planned end of active treatment (planned end of active treatment = Treatment 1-Day 78 for ASO12 group Treatment 1-Day 162 for ASO24 group and Treatment 2-Day 169 for ASO12-TI and ASO24-TI groups)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>


<!-- ############################### -->
<!-- ############################### -->
<!-- ######## FDA APPROVALS ######## -->
<!-- ############################### -->
<!-- ############################### -->

<br><h2 id="approvals">Drug Approvals/Applications</h2>
<h4><a href="#home">Home</a></h4>
<table border="1" summary="Long-term goals table" width="100%" cellspacing="0" cellpadding="0" class="fda">
  <thead>
    <tr>
      <th><h3>Company</h3></th>
      <th><h3>Update</h3></th>
      <th><h3>Trial ID</h3></th>
      <th><h3>Interest Level?</h3></th>
    </tr>
  </thead>
  <tbody>
  <tr>
    <td>Centessa Pharmaceuticals</td>
    <td>Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101 First LockBody Candidate for Solid Tumors</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/" target="_blank"></a></td><td><select class="form-select" id="select_form_84" name=""><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr style="background-color: #E1EBEE;">    <td>Deka Biosciences</td>
    <td>Deka Biosciences Receives FDA Clearance of DK210 (EGFR) Investigational New Drug Application</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT05704985" target="_blank">NCT05704985</a></td><td><select class="form-select" id="select_form_85" name="NCT05704985"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  <tr>
    <td>Alpha Biopharma</td>
    <td>Alpha Biopharma Submits New Drug Application for Zorifertinib a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS Metastases</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03653546" target="_blank">NCT03653546</a></td><td><select class="form-select" id="select_form_86" name="NCT03653546"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
<tr data-toggle="collapse" data-target="#demo9" class="accordion-toggle" style = "background-color: #E1EBEE;">    <td>Menarini</td>
    <td>Menarini's Orserdu Guardant's ctDNA CDx Net FDA Approval for ESR1-Mutated Breast Cancer Patients</td>
<td><a href="https://www.clinicaltrials.gov/ct2/show/NCT03778931" target="_blank">EMERALD (NCT03778931)</a></td><td><select class="form-select" id="select_form_87" name="NCT03778931"><option> </option><option>High Interest</option><option>Of Interest</option><option>No Interest</option></select></td>  </tr>
  </tbody>
</table>
<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_502" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['3/8/2019' '5/18/2016']</td>
          <td>Intravenous</td>
          <td>['840MG/14ML (60MG/ML)' '1200MG/20ML (60MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_504" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_505" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>durvalumab</td>
          <td>Imfinzi</td>
          <td>AstraZeneca UK Ltd</td>
          <td>5/1/2017</td>
          <td>Intravenous</td>
          <td>['120MG/2.4ML (50MG/ML)' '500MG/10ML (50MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_507" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>EUGIA PHARMA SPECLTS</td>
          <td>Aug 25 2021</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['500MG/2.5ML (200MG/ML)' '1GM/5ML (200MG/ML)']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>HIKMA</td>
          <td>Sep 16 2013</td>
          <td>CAPSULE;ORAL</td>
          <td>['25MG' '50MG']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>INGENUS PHARMS LLC</td>
          <td>['Nov 19 2021' 'Jul 30 2020']</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['500MG/2.5ML (200MG/ML)' '2GM/10ML (200MG/ML)' '1GM/5ML (200MG/ML)']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYTOXAN</td>
          <td>BAXTER HLTHCARE</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>['INJECTABLE;INJECTION' 'TABLET;ORAL']</td>
          <td>['25MG' '100MG/VIAL' '200MG/VIAL' '50MG']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYTOXAN (LYOPHILIZED)</td>
          <td>BAXTER HLTHCARE</td>
          <td>['Aug 30 1982' 'Approved Prior to Jan 1 1982' 'Sep 24 1985' 'Jan 4 1984' 'Dec 10 1985']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['2GM/VIAL' '1GM/VIAL' '500MG/VIAL']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>LYOPHILIZED CYTOXAN</td>
          <td>BAXTER HLTHCARE</td>
          <td>['Dec 5 1985' 'Dec 10 1985']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['100MG/VIAL' '200MG/VIAL']</td>
            </tr>
            <tr>
          <td>FLUDARABINE PHOSPHATE</td>
          <td>FLUDARA</td>
          <td>GENZYME CORP</td>
          <td>Apr 18 1991</td>
          <td>INJECTABLE;INJECTION</td>
          <td>50MG/VIAL</td>
            </tr>
            <tr>
          <td>FLUDARABINE PHOSPHATE</td>
          <td>FLUDARABINE PHOSPHATE</td>
          <td>SANDOZ</td>
          <td>Sep 21 2007</td>
          <td>INJECTABLE;INJECTION</td>
          <td>50MG/2ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>FLUDARABINE PHOSPHATE</td>
          <td>OFORTA</td>
          <td>SANOFI AVENTIS US</td>
          <td>Dec 18 2008</td>
          <td>TABLET;ORAL</td>
          <td>10MG</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_508" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['3/8/2019' '5/18/2016']</td>
          <td>Intravenous</td>
          <td>['840MG/14ML (60MG/ML)' '1200MG/20ML (60MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_509" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>sarilumab</td>
          <td>Kevzara</td>
          <td>Sanofi-Aventis U.S. LLC</td>
          <td>['5/22/2017' '4/13/2018']</td>
          <td>Subcutaneous</td>
          <td>['150MG/1.14ML' '200MG/1.14ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_510" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ACYCLOVIR</td>
          <td>AVACLYR</td>
          <td>FERA PHARMS LLC</td>
          <td>Mar 29 2019</td>
          <td>OINTMENT;OPHTHALMIC</td>
          <td>3%</td>
            </tr>
            <tr>
          <td>ACYCLOVIR</td>
          <td>SITAVIG</td>
          <td>EPI HLTH</td>
          <td>Apr 12 2013</td>
          <td>TABLET;BUCCAL</td>
          <td>50MG</td>
            </tr>
            <tr>
          <td>ACYCLOVIR</td>
          <td>ZOVIRAX</td>
          <td>BAUSCH</td>
          <td>['Mar 29 1982' 'Dec 30 2002']</td>
          <td>['CREAM;TOPICAL' 'OINTMENT;TOPICAL']</td>
          <td>5%</td>
            </tr>
            <tr>
          <td>ACYCLOVIR</td>
          <td>ZOVIRAX</td>
          <td>MYLAN</td>
          <td>['Apr 30 1991' 'Jan 25 1985' 'Dec 22 1989']</td>
          <td>['TABLET;ORAL' 'CAPSULE;ORAL' 'SUSPENSION;ORAL']</td>
          <td>['200MG/5ML' '800MG' '400MG' '200MG']</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_511" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['10MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '500MG/20ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_512" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '50MG/VIAL' '150MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)' '600MG/60ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_513" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>EUGIA PHARMA SPECLTS</td>
          <td>Aug 25 2021</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['500MG/2.5ML (200MG/ML)' '1GM/5ML (200MG/ML)']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>HIKMA</td>
          <td>Sep 16 2013</td>
          <td>CAPSULE;ORAL</td>
          <td>['25MG' '50MG']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>INGENUS PHARMS LLC</td>
          <td>['Nov 19 2021' 'Jul 30 2020']</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['500MG/2.5ML (200MG/ML)' '2GM/10ML (200MG/ML)' '1GM/5ML (200MG/ML)']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYTOXAN</td>
          <td>BAXTER HLTHCARE</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>['INJECTABLE;INJECTION' 'TABLET;ORAL']</td>
          <td>['25MG' '100MG/VIAL' '200MG/VIAL' '50MG']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYTOXAN (LYOPHILIZED)</td>
          <td>BAXTER HLTHCARE</td>
          <td>['Aug 30 1982' 'Approved Prior to Jan 1 1982' 'Sep 24 1985' 'Jan 4 1984' 'Dec 10 1985']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['2GM/VIAL' '1GM/VIAL' '500MG/VIAL']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>LYOPHILIZED CYTOXAN</td>
          <td>BAXTER HLTHCARE</td>
          <td>['Dec 5 1985' 'Dec 10 1985']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['100MG/VIAL' '200MG/VIAL']</td>
            </tr>
            <tr>
          <td>atezolizumab</td>
          <td>Tecentriq</td>
          <td>Genentech Inc.</td>
          <td>['3/8/2019' '5/18/2016']</td>
          <td>Intravenous</td>
          <td>['840MG/14ML (60MG/ML)' '1200MG/20ML (60MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['12/22/2014' '8/27/2021' '10/4/2017']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '40MG/4ML' '120MG/12ML' '100MG/10ML']</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_516" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_517" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_520" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>EUGIA PHARMA SPECLTS</td>
          <td>Aug 25 2021</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['500MG/2.5ML (200MG/ML)' '1GM/5ML (200MG/ML)']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>HIKMA</td>
          <td>Sep 16 2013</td>
          <td>CAPSULE;ORAL</td>
          <td>['25MG' '50MG']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>INGENUS PHARMS LLC</td>
          <td>['Nov 19 2021' 'Jul 30 2020']</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['500MG/2.5ML (200MG/ML)' '2GM/10ML (200MG/ML)' '1GM/5ML (200MG/ML)']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYTOXAN</td>
          <td>BAXTER HLTHCARE</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>['INJECTABLE;INJECTION' 'TABLET;ORAL']</td>
          <td>['25MG' '100MG/VIAL' '200MG/VIAL' '50MG']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>CYTOXAN (LYOPHILIZED)</td>
          <td>BAXTER HLTHCARE</td>
          <td>['Aug 30 1982' 'Approved Prior to Jan 1 1982' 'Sep 24 1985' 'Jan 4 1984' 'Dec 10 1985']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['2GM/VIAL' '1GM/VIAL' '500MG/VIAL']</td>
            </tr>
            <tr>
          <td>CYCLOPHOSPHAMIDE</td>
          <td>LYOPHILIZED CYTOXAN</td>
          <td>BAXTER HLTHCARE</td>
          <td>['Dec 5 1985' 'Dec 10 1985']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['100MG/VIAL' '200MG/VIAL']</td>
            </tr>
            <tr>
          <td>avelumab</td>
          <td>Bavencio</td>
          <td>EMD Serono Inc.</td>
          <td>3/23/2017</td>
          <td>Intravenous</td>
          <td>200MG/10ML (20MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_524" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCEFREZ</td>
          <td>SUN PHARM</td>
          <td>May 3 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/VIAL' '20MG/VIAL']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACCORD HLTHCARE</td>
          <td>['Jun 8 2011' 'Apr 20 2012']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/2ML (40MG/ML)' '80MG/4ML (20MG/ML)' '20MG/ML (20MG/ML)' '20MG/0.5ML (40MG/ML)' '160MG/8ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>ACTAVIS LLC</td>
          <td>['Sep 21 2015' 'Apr 12 2013']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '140MG/7ML (20MG/ML)' '20MG/ML (20MG/ML)' '80MG/4ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>APOTEX INC</td>
          <td>Jan 11 2012</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['80MG/2ML (40MG/ML)' '20MG/0.5ML (40MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>HOSPIRA INC</td>
          <td>['Jan 24 2017' 'Jun 23 2016' 'Mar 8 2011']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/16ML (10MG/ML)' '80MG/4ML (20MG/ML)' '160MG/8ML (20MG/ML)' '20MG/ML (20MG/ML)' '120MG/6ML (20MG/ML)' '20MG/2ML (10MG/ML)' '80MG/8ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>PFIZER LABS</td>
          <td>Mar 13 2014</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['200MG/20ML (10MG/ML)' '20MG/2ML (10MG/ML)' '130MG/13ML (10MG/ML)' '80MG/8ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SANDOZ</td>
          <td>Jun 29 2011</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['20MG/2ML (10MG/ML)' '160MG/16ML (10MG/ML)' '80MG/8ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SHILPA</td>
          <td>Dec 22 2015</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '20MG/ML (20MG/ML)' '80MG/4ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>DOCETAXEL</td>
          <td>SUN PHARM</td>
          <td>Jan 8 2019</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['160MG/8ML (20MG/ML)' '20MG/ML (20MG/ML)' '80MG/4ML (20MG/ML)']</td>
            </tr>
            <tr>
          <td>DOCETAXEL</td>
          <td>TAXOTERE</td>
          <td>SANOFI AVENTIS US</td>
          <td>['Aug 2 2010' 'Apr 13 2012' 'Aug 3 2010' 'May 14 1996']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['160MG/8ML (20MG/ML)' '40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**' '20MG/ML (20MG/ML)' '80MG/4ML (20MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_527" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '50MG/VIAL' '150MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)' '600MG/60ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>CISPLATIN</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Nov 8 1988</td>
          <td>INJECTABLE;INJECTION</td>
          <td>1MG/ML</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['10MG/VIAL' '50MG/VIAL']</td>
            </tr>
            <tr>
          <td>CISPLATIN</td>
          <td>PLATINOL-AQ</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Jul 18 1984</td>
          <td>INJECTABLE;INJECTION</td>
          <td>0.5MG/ML</td>
            </tr>
            <tr>
          <td>DEXAMETHASONE</td>
          <td>DECADERM</td>
          <td>MERCK</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>GEL;TOPICAL</td>
          <td>0.1%</td>
            </tr>
            <tr>
          <td>DEXAMETHASONE</td>
          <td>DECADRON</td>
          <td>MERCK</td>
          <td>['Jul 30 1982' 'Approved Prior to Jan 1 1982']</td>
          <td>['TABLET;ORAL' 'ELIXIR;ORAL']</td>
          <td>['1.5MG' '0.5MG/5ML' '4MG' '6MG' '0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**' '0.5MG' '0.75MG']</td>
            </tr>
            <tr>
          <td>DEXAMETHASONE</td>
          <td>DECASPRAY</td>
          <td>MERCK</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>AEROSOL;TOPICAL</td>
          <td>0.04% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**</td>
            </tr>
            <tr>
          <td>DEXAMETHASONE</td>
          <td>DEXTENZA</td>
          <td>OCULAR THERAPEUTIX</td>
          <td>Nov 30 2018</td>
          <td>INSERT;OPHTHALMIC</td>
          <td>0.4MG</td>
            </tr>
            <tr>
          <td>DEXAMETHASONE</td>
          <td>DEXYCU KIT</td>
          <td>EYEPOINT PHARMS</td>
          <td>Feb 9 2018</td>
          <td>SUSPENSION;INTRAOCULAR</td>
          <td>9%</td>
            </tr>
            <tr>
          <td>DEXAMETHASONE</td>
          <td>HEMADY</td>
          <td>DEXCEL PHARMA</td>
          <td>Oct 3 2019</td>
          <td>TABLET;ORAL</td>
          <td>20MG</td>
            </tr>
            <tr>
          <td>DEXAMETHASONE</td>
          <td>HEXADROL</td>
          <td>ASPEN GLOBAL INC</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>['TABLET;ORAL' 'ELIXIR;ORAL']</td>
          <td>['1.5MG' '0.5MG/5ML' '4MG' '0.5MG' '0.75MG']</td>
            </tr>
            <tr>
          <td>DEXAMETHASONE</td>
          <td>MAXIDEX</td>
          <td>NOVARTIS</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>SUSPENSION/DROPS;OPHTHALMIC</td>
          <td>0.1%</td>
            </tr>
            <tr>
          <td>DEXAMETHASONE</td>
          <td>OZURDEX</td>
          <td>ALLERGAN</td>
          <td>Jun 17 2009</td>
          <td>IMPLANT;INTRAVITREAL</td>
          <td>0.7MG</td>
            </tr>
            <tr>
          <td>FOLIC ACID</td>
          <td>FOLIC ACID</td>
          <td>LILLY</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>TABLET;ORAL</td>
          <td>1MG</td>
            </tr>
            <tr>
          <td>FOLIC ACID</td>
          <td>FOLVITE</td>
          <td>WYETH PHARMS INC</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>['INJECTABLE;INJECTION' 'TABLET;ORAL']</td>
          <td>['5MG/ML' '1MG']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMETREXED</td>
          <td>ACTAVIS LLC</td>
          <td>Aug 21 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>['1GM/40ML (25MG/ML)' '500MG/20ML (25MG/ML)' '100MG/4ML (25MG/ML)']</td>
            </tr>
            <tr>
          <td>PEMETREXED</td>
          <td>PEMFEXY</td>
          <td>EAGLE PHARMS</td>
          <td>Feb 8 2020</td>
          <td>SOLUTION;INTRAVENOUS</td>
          <td>500MG/20ML (25MG/ML)</td>
            </tr>
            <tr>
          <td>pembrolizumab</td>
          <td>Keytruda</td>
          <td>Merck Sharp & Dohme Corp.</td>
          <td>['1/15/2015' '9/4/2014']</td>
          <td>Intravenous</td>
          <td>['50MG' '100MG/4ML (25MG/ML)']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_529" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDEN PHARMA</td>
          <td>Mar 3 1989</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['450MG/VIAL' '50MG/VIAL' '150MG/VIAL']</td>
            </tr>
            <tr>
          <td>CARBOPLATIN</td>
          <td>PARAPLATIN</td>
          <td>CORDENPHARMA</td>
          <td>['Jul 14 2003' 'Jan 15 2004']</td>
          <td>INJECTABLE;INTRAVENOUS</td>
          <td>['150MG/15ML (10MG/ML)' '450MG/45ML (10MG/ML)' '50MG/5ML (10MG/ML)' '600MG/60ML (10MG/ML)']</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>ABRAXANE</td>
          <td>ABRAXIS BIOSCIENCE</td>
          <td>Jan 7 2005</td>
          <td>POWDER;INTRAVENOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>PACLITAXEL</td>
          <td>TAXOL</td>
          <td>HQ SPCLT PHARMA</td>
          <td>Dec 29 1992</td>
          <td>INJECTABLE;INJECTION</td>
          <td>6MG/ML</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_531" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>LOMUSTINE</td>
          <td>GLEOSTINE</td>
          <td>CORDEN PHARMA</td>
          <td>['Approved Prior to Jan 1 1982' 'Dec 19 2014']</td>
          <td>CAPSULE;ORAL</td>
          <td>['10MG' '100MG' '40MG' '5MG']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_534" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ABEMACICLIB</td>
          <td>VERZENIO</td>
          <td>ELI LILLY AND CO</td>
          <td>Sep 28 2017</td>
          <td>TABLET;ORAL</td>
          <td>['200MG' '50MG' '100MG' '150MG']</td>
            </tr>
            <tr>
          <td>FULVESTRANT</td>
          <td>FASLODEX</td>
          <td>ASTRAZENECA</td>
          <td>Apr 25 2002</td>
          <td>INJECTABLE;INTRAMUSCULAR</td>
          <td>50MG/ML</td>
            </tr>
            <tr>
          <td>FULVESTRANT</td>
          <td>FULVESTRANT</td>
          <td>FRESENIUS KABI USA</td>
          <td>May 20 2019</td>
          <td>SOLUTION;INTRAMUSCULAR</td>
          <td>250MG/5ML (50MG/ML)</td>
            </tr>
            <tr>
          <td>FULVESTRANT</td>
          <td>FULVESTRANT</td>
          <td>TEVA PHARMS USA INC</td>
          <td>Aug 19 2019</td>
          <td>SOLUTION;INTRAMUSCULAR</td>
          <td>250MG/5ML (50MG/ML)</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_537" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>AZACITIDINE</td>
          <td>AZACITIDINE</td>
          <td>ACTAVIS LLC</td>
          <td>Apr 29 2016</td>
          <td>POWDER;INTRAVENOUS SUBCUTANEOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>AZACITIDINE</td>
          <td>ONUREG</td>
          <td>CELGENE CORP</td>
          <td>Sep 1 2020</td>
          <td>TABLET;ORAL</td>
          <td>['300MG' '200MG']</td>
            </tr>
            <tr>
          <td>AZACITIDINE</td>
          <td>VIDAZA</td>
          <td>CELGENE</td>
          <td>May 19 2004</td>
          <td>POWDER;INTRAVENOUS SUBCUTANEOUS</td>
          <td>100MG/VIAL</td>
            </tr>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['50MG/10ML (5MG/ML)' '200MG/40ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['12/22/2014' '8/27/2021' '10/4/2017']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '40MG/4ML' '120MG/12ML' '100MG/10ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_540" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CELECOXIB</td>
          <td>CELEBREX</td>
          <td>UPJOHN</td>
          <td>['Dec 31 1998' 'Aug 29 2002' 'Dec 15 2006']</td>
          <td>CAPSULE;ORAL</td>
          <td>['50MG' '400MG' '100MG' '200MG']</td>
            </tr>
            <tr>
          <td>CELECOXIB</td>
          <td>ELYXYB</td>
          <td>BDSI</td>
          <td>May 5 2020</td>
          <td>SOLUTION;ORAL</td>
          <td>25MG/ML</td>
            </tr>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['50MG/10ML (5MG/ML)' '200MG/40ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['12/22/2014' '8/27/2021' '10/4/2017']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '40MG/4ML' '120MG/12ML' '100MG/10ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_541" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>CALCIPOTRIENE</td>
          <td>DOVONEX</td>
          <td>LEO PHARM</td>
          <td>Mar 3 1997</td>
          <td>SOLUTION;TOPICAL</td>
          <td>0.005%</td>
            </tr>
            <tr>
          <td>CALCIPOTRIENE</td>
          <td>DOVONEX</td>
          <td>LEO PHARMA AS</td>
          <td>['Jul 22 1996' 'Dec 29 1993']</td>
          <td>['OINTMENT;TOPICAL' 'CREAM;TOPICAL']</td>
          <td>0.005%</td>
            </tr>
            <tr>
          <td>CALCIPOTRIENE</td>
          <td>SORILUX</td>
          <td>MAYNE PHARMA</td>
          <td>Oct 6 2010</td>
          <td>AEROSOL FOAM;TOPICAL</td>
          <td>0.005%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>ADRUCIL</td>
          <td>PHARMACIA AND UPJOHN</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>INJECTABLE;INJECTION</td>
          <td>50MG/ML</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>CARAC</td>
          <td>VALEANT PHARMS NORTH</td>
          <td>Oct 27 2000</td>
          <td>CREAM;TOPICAL</td>
          <td>0.5%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>EFUDEX</td>
          <td>BAUSCH</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>['SOLUTION;TOPICAL' 'CREAM;TOPICAL']</td>
          <td>['2%' '5%']</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>FLUOROPLEX</td>
          <td>ALMIRALL</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>CREAM;TOPICAL</td>
          <td>1%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>FLUOROPLEX</td>
          <td>ELORAC</td>
          <td>Approved Prior to Jan 1 1982</td>
          <td>SOLUTION;TOPICAL</td>
          <td>1%</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>FLUOROURACIL</td>
          <td>SPECTRUM PHARMS</td>
          <td>['Approved Prior to Jan 1 1982' 'Jul 29 2016']</td>
          <td>INJECTABLE;INJECTION</td>
          <td>['2.5GM/50ML (50MG/ML)' '500MG/10ML (50MG/ML)']</td>
            </tr>
            <tr>
          <td>FLUOROURACIL</td>
          <td>TOLAK</td>
          <td>HILL DERMACEUTICALS</td>
          <td>Sep 18 2015</td>
          <td>CREAM;TOPICAL</td>
          <td>4%</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<!-- APPROVAL MODAL -->
<div class="modal fade" id="modal_542" tabindex="-1" role="dialog">
  <div class="modal-dialog modal-xl" role="document">
    <div class="modal-content">
    <!-- MODAL HEADER -->
      <div class="modal-header">
        <h4 class="modal-title">Previous Approvals</h4>
        <button type="button" class="close" data-dismiss="modal">&times;</button>
      </div>
      <!-- MODAL BODY -->
      <div class = "modal-body">
        <table class = "table table-striped">
          <thead>
            <tr>
          <th colspan="1">Proper Name</th>
          <th colspan="1">Proprietary Name</th>
          <th colspan="1">Applicant</th>
          <th colspan="1">Approval Date</th>
          <th colspan="1">Route of Administration</th>
          <th colspan="1">Strength</th>
            </tr>
          </thead>
          <tbody>
            <tr>
          <td>ipilimumab</td>
          <td>Yervoy</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>3/25/2011</td>
          <td>Intravenous</td>
          <td>['50MG/10ML (5MG/ML)' '200MG/40ML (5MG/ML)']</td>
            </tr>
            <tr>
          <td>nivolumab</td>
          <td>Opdivo</td>
          <td>Bristol-Myers Squibb Company</td>
          <td>['12/22/2014' '8/27/2021' '10/4/2017']</td>
          <td>Intravenous</td>
          <td>['240MG/24ML' '40MG/4ML' '120MG/12ML' '100MG/10ML']</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </div>
</div>

<center><button type="submit" value="submit">Submit</button></center></div></form><br><p><strong> <em>Disclaimer: This weekly digest is a product created exclusively by Lexidyne LLC, in collaboration with Janssen. The intended purpose is to identify clinical phase assets with new data related to lung cancer, priority mechanisms of action, local/intratumoral delivery, and/or increased potency for acquisition & business development consideration. </em> </strong></p><p><em>Sources used include but are not limited to: PubMed, ClinicalTrials.gov, ASCO, AACR, NIH, EU Clinical Trials Register, European Pharmaceutical Review, FDA.gov, PRNewsWire, FiercePharma, and BioSpace. </em> </p><center><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSffyxD4xZGkc99oZTy9lF0xPdIaqUMfCVpI2lWJzBkH3uDEag/viewform" target="_blank">Subscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdaRqTScaPylLdbIIgAaWs3eYn3wMcF_qF408_-D9caWHAgLw/viewform" target="_blank">Unsubscribe</a></div><div class="subscription"><p>|</p></div><div class="subscription"><a href="https://docs.google.com/forms/d/e/1FAIpQLSdSCfl2l2sV2jo-vFfym-VPpzyEs5M0cRRPY5TmBIZ-nR6gSQ/viewform" target="_blank">Feedback</a></div></center>